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A B S T R A C T
Background
Combined modality treatment (CMT) consisting of chemotherapy followed by localised radiotherapy is standard treatment for patients
with early stage Hodgkin lymphoma (HL). However, due to long term adverse effects such as secondary malignancies, the role of
radiotherapy has been questioned recently and some clinical study groups advocate chemotherapy only for this indication.
Objectives
We performed a systematic review with meta-analysis of randomised controlled trials (RCTs) comparing chemotherapy alone with
CMT in patients with early stage Hodgkin lymphoma with respect to response rate, progression-free survival (alternatively tumour
control) and overall survival (OS).
Search strategy
We searched MEDLINE, EMBASE and CENTRAL as well as conference proceedings from January 1980 to November 2010 for
randomised controlled trials comparing chemotherapy alone to the same chemotherapy regimen plus radiotherapy.
Selection criteria
Randomised controlled trials comparing chemotherapy alone with CMT in patients with early stage HL. Trials in which the chemo-
therapy differed between treatment arms were excluded. Trials with more than 20% of patients in advanced stage were also excluded.
Data collection and analysis
Effect measures used were hazard ratios (HR) for tumour control and OS as well as relative risks for response rates. Two review authors
independently extracted data and assessed quality of trials. We contacted study authors to obtain missing information. Since none of
the trials reported progression-free survival according to our definitions, all similar outcomes were evaluated as tumour control.
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Main results
Five RCTs involving 1245 patients were included. The HR was 0.41 (95% confidence interval (CI) 0.25 to 0.66) for tumour control
and 0.40 (95% CI 0.27 to 0.61) for OS for patients receiving CMT compared to chemotherapy alone. Complete response rates were
similar between treatment groups. In sensitivity analyses another six trials were included that did not fulfil the inclusion criteria of our
protocol but were considered relevant to the topic. These trials underlined the results of the main analysis.
Authors’ conclusions
Adding radiotherapy to chemotherapy improves tumour control and overall survival in patients with early stage Hodgkin lymphoma.
P L A I N L A N G U A G E S U M M A R Y
Treatment of early stage Hodgkin lymphoma
Hodgkin lymphoma is a malignancy of the lymphatic system, first described by Thomas Hodgkin. It can occur in children and adults,
but it is more common in the third decade of life. It is one of the most curable forms of cancer. Clinically speaking, there are four
stages of Hodgkin lymphoma. Generally, stages I and II are considered as early stage Hodgkin lymphoma and stages III and IV as
advanced stage Hodgkin lymphoma. Using risk factors such as presence or absence of bulky disease, age, erythrocyte sedimentation
rate and presence or absence of B symptoms, such as night sweats or fever, early stage Hodgkin lymphoma is further classified into early
favourable and early unfavourable stages. Treatment options for Hodgkin lymphoma are chemotherapy, radiotherapy or chemotherapy
plus radiotherapy. Nowadays chemotherapy plus radiotherapy to involved areas is considered as standard treatment for patients with
early stage Hodgkin lymphoma. Radiotherapy has comparatively more treatment related late side effects than chemotherapy, including
second malignancies. Perhaps, patients with early stage Hodgkin lymphoma can benefit more by avoiding radiotherapy and can be
treated with chemotherapy alone as effectively as with same chemotherapy plus radiotherapy. With this assumption we assess the role
of radiotherapy in the treatment of patients with early stage Hodgkin lymphoma. This systematic review compares chance of dying
(overall survival) and chance of tumour control in patients with early stage Hodgkin lymphoma after receiving chemotherapy alone
or chemotherapy plus radiotherapy. This review includes 1245 patients from five trials in the main analyses. The result of this review
is that the addition of radiotherapy to six cycles of chemotherapy is a better treatment option than six cycles of same chemotherapy
alone in patients with early stage Hodgkin lymphoma. In terms of five-year tumour control, approximately 5 patients would be needed
to treat with chemotherapy plus radiotherapy to prevent one additional relapse or progression in five years. For survival, 11 to 55
patients (depending on the risk of death) require treatment with additional radiotherapy to prevent one death in five years. Therefore
chemotherapy plus radiotherapy (combined modality treatment) is superior to the identical chemotherapy alone in patients with early
stage Hodgkin lymphoma.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Chemotherapy plus radiotherapy compared to chemotherapy alone for early stage Hodgkin lymphoma
Patient or population: Early stage Hodgkin lymphoma
Intervention: Chemotherapy plus radiotherapy
Comparison: Chemotherapy
Outcomes Illustrative comparative risks* Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk (95%
CI)
Chemotherapy Chemotherapy plus ra-
diotherapy
Overall survival
Hazard Ratio
(follow-up: median 5
years)
Low risk population1 HR 0.40
(0.27 to 0.6)
1245
(5)
⊕⊕⊕
moderate2
30 deaths per 1000 12 per 1000
(8 to 18)
High risk population1
150 deaths per 1000 63 per 1000
(43 to 93)
Tumour control
(follow-up: median 5
years)
Low risk population1 HR 0.41
(0.25 to 0.66)
1202
(4)
⊕⊕⊕
moderate3
100 progresses or re-
lapses per 1000
42 per 1000
(26 to 67)
High risk population1
300 progresses or re-
lapses per 1000
136 per 1000
(85 to 210)
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Complete Response
Rate
Low risk population4 RR 1.07
(0.98 to 1.17)
653
(4)
⊕⊕⊕
moderate5
960 complete responses
per 1000
1027 per 1000
(941 to 1123)
High risk population4
650 complete responses
per 1000
696 per 1000
(637 to 760)
Long term secondary
malignancies
See comment See comment Not estimable - See comment As most of the trials had a
median observation time
of less than 10 years, long
term information on sec-
ondarymalignancies can-
not be expected.6
Acute adverse effects See comment See comment Not estimable - See comment Acute adverse effects
were reported differently
in the studies and are sim-
ilar in both groups.7
Long term toxicities See comment See comment Not estimable - See comment Long term toxicities other
than secondary malig-
nancies are not reported.
8
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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1 The risk for the low risk population (of patients with early stage Hodgkin lymphoma) was taken from the trial with the lowest rates of tumour control at 5 years the EORTC-GELA H9-F trial.
The high risk rate is approximately the risk in the GATLA 9-H-77.
2 The supplemental analyses shifted the effect estimate (see results section). For this reason, the outcome overall survival was downgraded to moderate.
3 The definitions of tumour control varied between trials. In some trials the choice of tumour control outcome to be reported may have been guided by strength of the effect. These
heterogeneous definitions also lead to an imprecise estimate of the effect or may be considered a publication bias. The effect of these heterogeneous definitions is downgraded here. The
same cause is not downgraded in another section again.
4 The complete response rate for the low risk population is the highest CR rate reported in an included trial in this review (MSKCC #90-44). The rate for the low risk population is the lowest
CR rate reported in this review (CALGB 7751). This estimate of high risk may no longer be relevant today, as ABVD produces much higher rates of CR than CVPP:
5 Note that for trials using only ABVD the RR is 1.02 (0.95 to 1.09).
6 A non-systematic search of cohorts of Hodgkin lymphoma survivors did not reveal any cohorts that presented 20-year secondary malignancy rates for early stage patients treated with
chemotherapy alone versus chemotherapy plus radiotherapy. Cohorts of all patients suggest a higher risk of secondary malignancies for patients receiving any type of radiotherapy. The
question of secondary malignancies is addressed in another Cochrane review of individual patient data (Franklin 2005). This review reports 4% versus 5% cumulative incidence of secondary
malignancies at 20 years. This rate is much lower than the rates for patients with advanced stages (~20%).
7 Due to diversity in reporting, adverse effects were not meta-analysed. Common diverse effects reported are nausea and vomiting, alopecia, grade III neutropenia and grade I-II thrombopenia.
Rare (<2%) are bleomycin induced lung disease, infection-related mortality or high grade neurotoxicity.
8 In cohorts of patients with Hodgkin lymphoma infertility and chronic cardiac disease are relatively common. However information on how frequent these effects are in early stage patients
treated with the treatments discussed in this review was not reported.
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B A C K G R O U N D
Description of the condition
Hodgkin lymphoma (HL) is one of the most common malignan-
cies in young adults (Swerdlow 2003; Thomas 2002). It is a ma-
lignancy of the lymph nodes and lymphatic system with possible
involvement of other organs. The disease is rare with an annual in-
cidence of approximately two to three per 100,000 in most coun-
tries (DeVita 1997; Diehl 2005; Mauch 1999) and occurs mostly
in young people, the incidence being greatest in the third decade of
life (Mueller 1999). Factors associated with Hodgkin lymphoma
include family history, viral exposures, and immune suppression
(Glaser 1996).
Staging of HL is based on the Ann Arbor system (Carbone 1971),
with the addition of a definition of bulky disease (largest tumour
diameter > 10 cm), often referred to as the Cotswold modifica-
tion (Lister 1989). Information about prognostic factors such as
mediastinal mass, other bulky nodal disease, and extent of sub-
diaphragmatic disease is included in this classification. Generally,
HL is differentiated into early stage HL and advanced stage HL.
On the basis of clinical staging and risk factors, patients are usu-
ally assigned to early favourable, early unfavourable and advanced
stages (Engert 2007; Klimm 2005). However, there are still small
differences in the definition of risk factors used and in the classifi-
cation of certain subgroups of patients among the different study
groups in Europe and the USA.
Description of the intervention
Usually patients with early stage Hodgkin lymphoma receive
two to six cycles of ABVD (adriamycin, bleomycin, vinblastine,
and dacarbazine) in combination with involved-field radiotherapy
(IF-RT) (Diehl 2005; Engert 2007; Meyer 2005; MSKCC trial
#90-44). Depending on the intensity and dose of treatment given,
long term complications such as secondary malignancies (Franklin
2005), cardiac disease (Adams 2004) and infertility are common
in Hodgkin survivors. For patients with early stage disease, the
20 year cumulative secondary malignancy rate is estimated to be
between four percent and 20 percent (Franklin 2005; Ng 2002a).
Risk factors for secondary malignancies (and cardiac disease) are
the choice and dose of radiotherapy and chemotherapy (Aleman
2003; Bhatia 2003; Dores 2002; Franklin 2005; Green 2000; Ng
2002a; Ng 2002b; Swerdlow 2000; van Leeuwen 2000). Unfortu-
nately, no long-term comparison of combined modality treatment
(CMT), consisting of chemotherapy plus radiotherapy, with che-
motherapy alone was possible in cohorts of Hodgkin survivors,
in part due to the changes in treatment regimens over time (Ng
2002a). Nonetheless, to avoid additional radiation-induced tox-
icity, chemotherapy-only treatment for patients with early stage
Hodgkin lymphoma has been advocated (Canellos 2005; Meyer
2005a). This notionwas supported by two clinical trials comparing
combined modality treatment with chemotherapy alone in which
no significant survival disadvantage was observed in patients re-
ceiving chemotherapy alone (Meyer 2005;MSKCC trial #90-44).
However, one of these trials compared two cycles of chemotherapy
plus radiotherapy with four to six cycles of chemotherapy.
How the intervention might work
Chemotherpay (CT) and radiotherapy (RT) act on differentiat-
ing cells, prone to damage, and stop their growth and ultimately
damage them, as result tumour mass shrinks. Along with tumour
cure normal body cells are also affected after treatment resulting
in treatment related side effects.
Biologic basis of chemotherapy
The most commonly used chemotherapeutic drugs in the treat-
ment of early stage HL are classified as follows.
• Alkylating agents: cyclophospahamide, mechlorethamine,
procarbazine, dacarbazine, cisplatine.
• Anti-tumour antibiotics: bleomycine, doxorubicine
(adriamycin), epirubicine, etoposide.
• Anti-mitotic agents: vincristine, vinblastine.
• Steroid hormones: prednisone.
Alkylating agents and anti-tumour antibiotics are phase-nonspe-
cific chemotherapeutic drugs, which can injure DNA at any phase
of cell cycle but appear to then block in S-phase or G2 at a check
point in a cell cycle before cell division (Sausville 2005). Anti-mi-
totic agents and steroid hormones are phase-specific chemothera-
peutic drugs. Anti-mitotic agents act in M-phase and prevent tu-
mour cell division by destroying mitotic spindle and anti-metabo-
lites act in S-phase and prevent replication of tumour cell’s DNA,
stopping tumour cell proliferation. Steroid hormones act in M-
phase by suppressing the mitosis in lymphocytes (Chaber 2006).
Biologic basis of radiotherapy
In the target tumour tissue (lymphnodes), RTdirectly damages the
DNA of tumour cells and prevents further cell differentiation of
tumour cells and shrinks the tumour mass. Indirectly, it generates
free radicals from cell water that are capable of damaging DNA,
cell membranes, proteins and organelles. Although radiation can
interfere with many cellular processes, many experts feel that cell
must undergo a double stranded DNA break from radiation in
order to be killed (Hahn 2005). RT is effective when it exerts
greater cytotoxic effects on tumour cells than on normal tissues
and/or the cells of the normal tissues are more capable of repairing
the radiation damage than the tumour cells.
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Why it is important to do this review
In recent years, a concept of minimal curative therapy with great-
est efficacy and least toxicity has emerged in the treatment of early
stage HL (Connors 2001; Connors 2005). This concept is based
on the assumption that avoidance of RT would result in fewer
deaths from late-effects and the long-term survival would be at
least comparable and possibly better for patients treated with CT
alone in early stage HL. To test this assumption, we performed
a systematic review with meta-analysis of randomised controlled
trials comparing chemotherapy alone with chemotherapy plus ra-
diotherapy in patients with early stage Hodgkin lymphoma with
respect to adverse events, response rate, progression-free survival
or similar outcomes and overall survival (OS).
O B J E C T I V E S
The objective of the review was to analyse the efficacy of CT-
alone compared to CMT in patients with early favourable and
early unfavourable stage HL (clinical stage (CS) I and CS II),
with respect to OS as primary outcome measure and progression-
free survival (PFS) or similar, response rate and adverse events as
secondary outcome measures. Outcomes similar to progression-
free survival are called “tumour control” in this review.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs comparing CT-alone with combined modal-
ity treatment (CMT) consisting of chemotherapy plus radiother-
apy in newly diagnosed patients with CS I and CS II HL (early
favourable and early unfavourable stages of HL). We excluded
RCTs comparing CT-alone with CMT in patients with all stages
of HL if more than 20% of patients had advanced disease. We
used the risk factor definitions as described in the individual tri-
als. The terms “early stage” and “limited-stage” were considered
equivalent. We excluded quasi randomised trials. Trials including
fewer than 10 participants per arm were also excluded according
to the protocol. No such trials were found.
Types of participants
We included both male and female patients of all ages, with newly
confirmed diagnosis of early stage HL (CS I and II) without any
prior treatment for HL. If there were more than 20% of the par-
ticipants with advanced stage, the trial was excluded. Post hoc,
we included such trials in sensitivity analyses. If possible we used
subgroup data of early stages.
Types of interventions
We compared CT (single agent or multiple agent, regardless of
dose, number of cycles and intervention time) and both CT plus
RT (regardless of dose, field used and intervention time) as primary
treatment for patients with CS I and CS II HL (early favourable
and early unfavourable stages of HL). We excluded trials if the
CT regimen was not identical in both study arms. Post hoc, we
included such trials in sensitivity analyses of overall survival and
tumour control.
Types of outcome measures
Primary outcomes
We evaluated overall survival as the primary endpoint. The pre-
ferred definition of OS was “time from entry onto the clinical trial
until death as a result of any cause” (Cheson 2007).
Secondary outcomes
Overall response rate (ORR) and complete response (CR) were
evaluated as secondary endpoints. The definitions of overall re-
sponse and complete response were used as given in the publica-
tion. If only complete response and partial response were given,
the overall response rate was calculated as complete response plus
partial response. Further, we also planned to compare progression-
free survival (PFS) between CT-alone and CMT for patients with
early stage HL. Because no trials reported PFS according to our
definition (time to tumour progression, relapse or death), we ac-
cepted other tumour control outcomes and evaluated these. Fi-
nally we evaluated all reported adverse events.
Search methods for identification of studies
We used search methods as suggested in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2008) and by
theCochrane Haematological Malignancies Group (CHMG). No
language restriction was applied to reduce the language bias, espe-
cially English language bias, as studies showing an intervention to
be effective are more likely to be published in English (Dickersin
1993; Egger 1997; Juni 2002). We designed a search strategy with
the assistance of the Trials Search Co-ordinator of CHMG for
health-related bibliographic databases.
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Electronic searches
We searched Cochrane Central Register of Controlled Trials
(CENTRAL) (see Appendix 1) and MEDLINE (see Appendix 2)
for the years January 1977 until November 2010. We searched
EMBASE (see Appendix 3) for the years January 1977 until Febru-
ary 2009.
Searching other resources
We hand-searched the proceedings of the American Society of
Hematology for the years 1977 to 2009, except for the year 1979.
We searched abstracts of the American Society of Clinical Oncol-
ogy (ASCO) from 1977 to 2010, except for the year 1990. Pro-
ceedings of the International Symposium onHodgkin Lymphoma
(IHSL) were searched from 2004 on. Additionally, two authors
performed a cross reference search (screening) of references in pri-
mary studies and review articles and checked databases of ongoing
clinical trials.
Data collection and analysis
Two authors independently extracted data from full text publica-
tions or from abstract publication and assessed the quality of trials.
Selection of studies
Two authors independently screened the titles and abstracts of
potentially relevant RCTs comparing CT-alone with CMT (with
identical CT regimen in both arms) in newly diagnosed patients
with CS I and CS II (favourable and early unfavourable stages
of HL) according to predefined criteria. Both authors identified
eligible trials using a “study eligibility form” which included the
following eligibility criteria:
1. Is the study described as randomised?
2. Did ≥ 80% of the included participants have early stage
HL?
3. Were comparison arms treated with CT-alone in one arm
and CMT in other arm or arms?
4. Was the same CT regimen used in the comparison arms?
5. Did the study document OS, tumour control (progression-
free survival or similar) or response rate as outcome measure?
Studies that met the above mentioned inclusion criteria from
screening titles and abstracts were retrieved as full text publications
for detailed evaluation. We referred any disagreement between au-
thors to a third author and a decision was made by consensus.
Data extraction and management
We obtained the full text versions of the publications and abstracts
of selected trials for data extraction.
Assessment of risk of bias in included studies
Two authors independently assessed the risk of bias (quality) in
included trials. Please note that this assessment differed from the
one proposed in the protocol in order to comply with the new
Cochrane Handbook for Systematic Reviews of Interventions. We
assessed the following domains:
1. Was the allocation sequence adequately generated?
2. Was allocation adequately concealed?
3. Was knowledge of allocated intervention adequately
prevented during trial from outcome assessors?
4. Were incomplete outcome data adequately addressed?
5. Are reports of the trial free of suggestion of selective
outcome reporting?
6. Was the trial apparently free of other problems that could
put it at risk of bias (e.g. similarity of patients’ characteristics at
baseline)
We referred any disagreement between reviewers to a third reviewer
and a decision was made by consensus. Trials were not assessed
blind, since the review authors knew the study author’s name,
institution, source of publication and results of publication.
Measures of treatment effect
Time-to-event data
Treatment effect measures of individual trials were estimated as
hazard ratios (HRs) for OS and tumour control from survival
analysis, using methods described by Parmar 1998 and Tierney
2007. As no hazard ratios were reported, the HRs for OS and
tumour control were estimated indirectly, using logrank statistics
through reported P values and number of events in comparison
arms. If P values were not reported, we estimated HRs for OS and
tumour control using survival curves data. Finally, log HRs with
standard errors (SEs) were calculated and entered in RevMan 5
for analysis.
In sensitivity analyses, we included additional trials. For some of
these trials there were insufficient data (Nachman 2002; Picardi
2007) for tumour control for the calculation of HRs. These HR
estimates were improper as they were calculated from the RR and
without any time-to-event information. The analysis was repeated
without the improper estimates.
Dichotomous data
The treatment effect measures of individual trials for ORR and
CR were calculated as relative risks (RRs).
Dealing with missing data
Missing outcome data
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Each trial was assessed for missing patients after randomisation
due to drop outs, participants lost to follow-up or protocol vio-
lations and number of patients not included in the primary (OS)
and secondary outcomes (tumour control and response rates) anal-
yses were calculated. Trials excluding more than 10% of the ran-
domised patients from outcomes analyses were included in the
review and a sensitivity analysis was performed to check the ro-
bustness of the results.
Missing information
To obtain missing information, we contacted study authors and
checked previous trial reports of the same investigators.
Assessment of heterogeneity
A P value of the homogeneity test (Chi2 test) was used to identify
the statistical heterogeneity between trials with the significance
level being set at P < 0.1. The extent of inconsistency (heterogene-
ity) across the trials was quantified by performing I² statistics in
the meta-analyses (Higgins 2002; Higgins 2003). A value of I² ≥
50% was considered as substantial heterogeneity across the trials
in the meta-analysis.
Assessment of reporting biases
We drew a funnel plot to detect the reporting (publication) and
related biases in the meta-analyses that contained at least four in-
cluded trials. Due to the small number of trials, no linear regres-
sion test (Egger 1997a) was performed.
Data synthesis
We pooled estimated HRs for OS of individual trials using the
“Generic Inverse Variance method” using a random-effects model.
We pooled estimated relative risks (RRs) for complete response
and overall response rate using Der Simonian-Laird method.
We calculated the number needed to treat to benefit with 95%
confidence intervals for five-year overall survival or five-year tu-
mour control for hazard ratios as described by Altman 1999.
Subgroup analysis and investigation of heterogeneity
We planned the following subgroup analyses to investigate the
potential causes of heterogeneity with different treatment effects
in different groups:
1. Proportion of patients with early favourable stage HL versus
early unfavourable stage HL.
2. CS I HL versus CS II HL.
3. Bulky versus non-bulky disease e.g. i) with mediastinal mass
versus without mediastinal mass ii) with > 3 involved nodal areas
versus < 3 involved nodal areas.
4. Different age groups e.g. < 18 years versus 18 to 50 years
versus > 50 years.
5. Male versus female patients.
6. Different sequence of interventions e.g. CT + RT versus RT
+ CT versus CT-RT-CT.
7. Different RT treatment regimens e.g. IF-RT versus
extended field radiotherapy (EF-RT).
8. Different CT regimens e.g. ABVD versus CVPP
(cyclophosphamide, vinblastine, procarbazine, prednisone)
versus EBVP (epirubicin, bleomycin, vinblastine, prednisone).
9. Median length of follow-up (six years or less, more than 6
years)
10. 4-year survival in the CT-alone group (> 90%, 80% to
90%)
Of these planed subgroups, numbers 2, 4, and 5 could not be
performed due to lack of data. Post hoc, we performed subgroup
analyses including trials that did not fulfil the inclusion criteria of
the protocol, but were considered to give information relevant to
the review (for a description of these trials see the Results section).
We assessed subgroup differences using the test for subgroup dif-
ferences in RevMan5.
Sensitivity analysis
We performed a sensitivity analysis to assess the robustness of
the overall result with respect to quality and trial design. Using
sensitivity analysis we explored:
1. Measures of study quality (ITT-analysis, > 10% of patients
not evaluated vs. ≤ 10% not evaluated, allocation concealment).
2. The influence of a single large study on the overall result.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
Our literature search produced 2800 potentially relevant refer-
ences related to the treatment of patients with early stage HL. Of
these, 2749 were excluded at the initial stage of screening because
they did not fulfil our predefined inclusion criteria. The remaining
51 publications were retrieved as full text publications or abstract
publications for detailed evaluation.Of these 51 trials, we excluded
41 and finally 5 trials (10 publications) with 1245 patients were
formally included in the main analyses of this review. The over-
all number of trials screened, identified, selected, excluded and
included was documented with reasons according to QUOROM
flow diagram (Moher 1999) (Figure 1).
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Figure 1. QUOROM-DIAGRAM: Note that the reasons for exclusion are hierarchical, i.e. reasons higher in
the list were considered before those lower down.
Among the excluded trials (according to our review protocol) six
trials were included in sensitivity analyses post hoc, as they yielded
relevant information to the underlying clinical question. Five tri-
als included more than 20% of patients in advanced stages (Kung
2006; Laskar 2004; Nachman 2002; O’Dwyer 1985; Picardi
2007).We identified two trials (Kung 2006;Meyer 2005) inwhich
the patients in the chemotherapy alone group receivedmore cycles
of chemotherapy than the patients in the chemotherapy plus ra-
diotherapy group, one of which also included patients of all stages
of HL. Characteristics and main results of these trials are described
in Table 1.
Table 1. Characteristics of selected excluded trials
Trial Patients Time of ran-
domisation
Chemother-
apy and radio-
therapy
Subgroup of
early stage pa-
tients?
Length of ob-
servation
Overall
survival
Progres-
sion-free sur-
vival (or event-
free survival)
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Table 1. Characteristics of selected excluded trials (Continued)
Laskar 2004 All stages, age
< 70 years
in CR 6 X ABVD
+ (mainly) IF-
RT vs. 6 X
ABVD
yes; stage I-II:
CMT: 55
CT: 44
8 years CMT: 100%
CT: 98%
CMT: 97%
CT: 94%
Nachman
2002
Children with
any stage of
HL
in CR Early stage: 4X
COPP/ABV
+
low dose IF-
RT
vs. 4X COPP/
ABV
yes; early stage
(I-II) patients:
CMT: 189
CT: 173
3 years 100% in both
groups
CMT: 97% +/
- 1.7 (SE)
CT: 91% +/-
2.8 (SE)
O’Dwyer
1985;
stages IB to
IIIA
Before CT MOPP +RT
vs. MOPP
no;
CMT : 16
CT: 17
6 years CMT: 3
deaths
CT: 2 deaths
CMT: 3 pro-
gression or re-
lapse
CT: 4 progres-
sion or relapse
Picardi 2007 bulky
HLwith resid-
ual masses in
CT that were
PET negative
at restaging af-
ter CT
In CR 6 X VEBEP +
RT vs.
6 X VEBEP
yes;
CMT: 53
CT: 52
5 years 100% in both
groups
# of patients
who relapsed:
CMT: 0/53
CT: 6/52
Trials in which the number of cycles varied between the chemotherapy alone and the chemotherapy plus radiotherapy group
Kung 2006 Children, PS
I-IIIA
In CR or PR 4 X MOPP/
ABVD + IF-
RT vs.
6 X MOPP/
ABVD
no (31% IIIA) 8 years CMT: 96.8%
+/- 2.7%
CT: 93.6% +/
- 3.9%
P = 0.79
CMT: 91.1%
+/- 4.5%
CT: 82.6% +/
- 5.9%
P = 0.15
Meyer 2005 Early stage (I-
IIA); absence
of bulky dis-
ease
Before trial 2 X ABVD +
subtotal nodal
irradiation vs.
4-6 X ABVD
only early
stage
5 years HR = 1.82
[0.58 to 5.68]
HR = 0.33
[0.14 to 0.80]
Included studies
The characteristics of included studies are also summarized in
Table 2.
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Table 2. Characteristics of included trials
Trial Inclusion crite-
ria
Number of pa-
tients analysed
Treatment Median fol-
low-up in years
(range)
ITT- analysis Not evaluated or
lost to follow-up
(%)
Mexico B2H031 CS I to II Supra-
di-
aphragmatic dis-
ease and Bulky
disease
99 6xABVD 11.4 (6.3 to
16.5)
No 6
102 6xABVD+ IF-
RT
CALGB 7751
Interim results
“poor prognosis”
PS I or II
18 6xCVPP. 2 (0 to ?) No 32
19 6xCVPP+ IF-
RT
EORTC-GELA
H9-F
Interim results
CS I - II Supra-
diaphrag-
matic disease All
of the favourable
features (age <
50 years, ESR
< 50 mm/h or
B symptoms and
ESR < 30 mm/h,
mediastinal-
thoracic ratio <
0.35) CR after 6
cycles EBVP
130 6xEBVP 4.3 years (1.2 to
6.8)
Yes 0
448 6x/EBVP + 36
Gy IF-RT or 20
Gy IF-RT
GATLA 9-H-77 CS I and II, 173
patients
with favourable
and 104 patients
with un-
favourable char-
acteristics (age >
45, sites > 2,
bulky tumour)
142 6xCVPP 4 years (not re-
ported)
No 6
135 6xCVPP + IF-
RT
MSKCC trial
#90-44
CS
I to IIIA with-
out bulky dis-
ease, 13%
with CS IIIA ~
30 to 50% un-
favourable
disease.
76 6xABVD 5.6 (0.1 to 10.4) Yes
(OS)
0 (OS)
9 (CR, tumour
control)
12Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Characteristics of included trials (Continued)
76 6xABVD + IF-
RT or EF-RT
Five trials (CALGB 7751; EORTC-GELA H9-F; GATLA 9-H-
77; Mexico B2H031; MSKCC trial #90-44) were included in the
review. The earliest trial recruited in the 1970s and the latest in
1998 to 2004. The data were extracted from full text publications
for four trials and for one trial (EORTC-GELA H9-F) data were
extracted from the abstract.
Design
Of the five included trials, three were two-armed randomised con-
trolled trials and two were three-armed randomised controlled tri-
als. Mexico B2H031 randomised to radiotherapy alone, CMT or
CT-alone. The radiotherapy arm was not included in this system-
atic review. EORTC-GELA H9-F randomised to chemotherapy
alone, CMT with 36 Gy or CMT with 20 Gy. The two radiother-
apy dosages were evaluated together in this review.There were three
multi-centre trials and for two of them (CALGB 7751; GATLA
9-H-77) it was not clear whether they were single centre or multi-
centre.
Sample sizes
The smallest trial included 55 (37 analysed) patients (CALGB
7751) and the largest trial 578 patients (EORTC-GELA H9-F).
Location
The included trials came from a range of research groups from
different countries. The trials were conducted in the following
countries: one trial in USA (CALGB 7751); one trial in USA and
Canada (MSKCC trial #90-44), one trial in different institutions
of European countries (EORTC-GELAH9-F); one trial inMexico
(Mexico B2H031); one trial in Argentina (GATLA 9-H-77).
Participants
A total of 1245 male and female patients of all ages, with a newly
confirmed diagnosis of clinical stage (CS) I and II or pathologic
stage (PS) I and II HL and without previous treatment were in-
cluded. For most patients, histopathologic diagnosis was made
according to Rye modification of Lukes and Butler classification
(Lukes 1966).
Interventions
Patients from included trials were treated with six cycles of CT-
alone or six cycles of same CT plus radiotherapy (CMT). For in-
cluded trials, the following CT regimens were used: adriamycin,
bleomycin, vinblastine, and dacarbazine (ABVD) in two trials
(Mexico B2H031; MSKCC trial #90-44); CVPP (cyclophos-
phamide, vinblastine, procarbazine, prednisone) for two trials
(CALGB 7751; GATLA 9-H-77); EBVP (epirubicin, bleomycin,
vinblastine, prednisone) for one trial (EORTC-GELAH9-F). The
size of radiation fields used for the delivery of radiotherapy were
as follows: IF-RT in three trials (CALGB 7751; EORTC-GELA
H9-F; GATLA 9-H-77); extended-field radiotherapy in two tri-
als (Mexico B2H031; MSKCC trial #90-44). Two trials (GATLA
9-H-77; Mexico B2H031) administrated three cycles of CT be-
fore and after RT (sandwich technique), in the other trials CT was
administered prior to RT.
Outcomes
Primary outcome measure
All included trials analysed overall survival. The median observa-
tion times for overall survival were as follows: 11 years for one trial
(Mexico B2H031); seven years for one trial (GATLA 9-H-77);
four to five years for two trials (EORTC-GELA H9-F; MSKCC
trial #90-44); 22 months for one trial (CALGB 7751).
Secondary outcome measures
None of the included trials reported PFS data according to our
definition (time to progression or death of any cause). All trials
except CALGB 7751 reported some type of progression outcome
(see Table 3). Four trials (CALGB 7751; GATLA 9-H-77;Mexico
B2H031; MSKCC trial #90-44) reported response rate.
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Table 3. Definitions of progression outcomes
Trial Definition of progression outcome
Mexico B2H031 Contradictory definitions. In the methods section: “Disease free survival was calculated for CR patients
from the beginning of treatment until clinically or radiologically and biopsy proven relapse.” In the results
section the percent disease free were calculated based on the full population.
EORTC-GELA H9-F Definition of disease-free survival not reported. (Note all patients are in CR at the time of randomisation.)
GATLA 9-H-77 Patients who failed to respond were evaluated as relapsed at first month. Patients in CR were evaluated from
date of CR to date of first relapse or death.
MSKCC trial #90-44 Time from enrolment until any progression of disease.
Funding
Academic funding was provided for three trials (CALGB 7751;
GATLA 9-H-77; MSKCC trial #90-44). Source of funding was
not described by the remaining two trials.
Conflict of interest
No trial reported information with respect to conflict of interest.
Excluded studies
Among the excluded trials (according to our review protocol) a
number of trials were included in sensitivity analyses post hoc, as
they yielded relevant information to the underlying clinical ques-
tion. Three trials (566 patients) included patients of all stages
and reported some subgroup information for early stage patients
(Laskar 2004; Nachman 2002; Picardi 2007). One of these trials
examined patients with bulky disease and residualmasses after VE-
BEP chemotherapy who were PET negative (Picardi 2007). One
trial included patients in stages I through IIIa which included very
few patients (O’Dwyer 1985). Finally we identified two trials in
which the patients in the chemotherapy alone group receivedmore
cycles of chemotherapy than the patients in the chemotherapy plus
radiotherapy group (Kung 2006; Meyer 2005). The chemothera-
pies used in these trials were ABVD (Laskar 2004; Meyer 2005),
COPP/ABV (Nachman 2002), VEBEP (Picardi 2007), MOPP/
ABVD (Kung 2006) and MOPP (O’Dwyer 1985). Their charac-
teristics and main outcomes are presented in Table 1.
For information on excluded trials see Characteristics of excluded
studies, where reasons for the exclusion of important excluded
trials are listed. For the publication on bleomycin toxicity, where
no information for the relevant comparison was found, basic out-
comes are also reported.
A total of 41 articles were excluded after detailed evaluation of full
text publications. The main reasons for exclusion were:
• 13 non-randomised comparisons or reviews
• 17 not CT versus CMT
• 1 not Hodgkin lymphoma
• 1 only advanced stages
• 4 < 80% early stage patients (included in sensitivity
analyses)
• 3 chemotherapy regimen differed
• 2 publications of “one trial”, where MSKCC patients were
randomised to CT vs CMT or different CT plus differing
radiotherapy schemes were followed for pulmonary function for
approximately one year. The 45 patients with a relevant
comparison to this review are presumably included in the
MSKCC trial #90-44. For more details see Characteristics of
excluded studies.
Some of these publications are described under Characteristics of
excluded studies.
Risk of bias in included studies
See “risk of bias tables” of included trials and for an overview of
the results please see Figure 2.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
In the EORTC-GELA H9-F trial the chemotherapy alone arm
ended early due to stopping rules.Unfortunately it was not possible
to receive the data on patients receiving additional radiotherapy
only up to the date the chemotherapy alone arm was stopped.
Allocation
Treatment allocation of patients was performed at a central tri-
als office for one trial (MSKCC trial #90-44); no information
was available for the other trials. No trial reported the sequence
generation. Sequence generation and allocation concealment was
judged to probably be adequate in large multi-centre trials that
have previously adequately randomised and whose allocation was
previously adequately concealed (EORTC-GELAH9-F;MSKCC
trial #90-44).
Blinding
As radiotherapy is difficult to blind, one does not expect the pa-
tients to be blinded. However, none of the other trials reported in-
formation about blinding of outcome assessors or statisticians. As
blinding of the outcome assessors is considered important for this
review, all trials were judged “unclear” for the question of blinding.
Incomplete outcome data
Overall survival
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Most trials described missing outcome data in detail (GATLA
9-H-77) or included all randomised patients in the analysis with-
out reporting any missing data for this outcome (EORTC-GELA
H9-F; MSKCC trial #90-44). In the Mexico B2H031 trial 20/
327 patients were missing from the analyses without further infor-
mation (this information was not available only for the two arms
included in this review). No trial reported imputation of results
for missing data in the context of an intention-to-treat analysis.
A high proportion of patients were not analysed in the CALGB
7751 trial but the trial has a low weight in the meta-analysis due
to the small number of patients (36 patients evaluated). Due to
the small proportion of missing data and the detailed descriptions
in most trials, we do not believe that bias was introduced into the
meta-analysis by missing data.
For the predefined subgroup analyses we used a strict definition
of intention-to-treat analysis (Deeks 2008). Therefore trials that
did not include all patients in the analysis and did not describe
the method of analysis were not considered to have performed
an intention-to-treat analysis (CALGB 7751; GATLA 9-H-77;
Mexico B2H031).
Secondary outcomes
There were more missing data among the secondary outcomes
response rate and tumour control.
Selective reporting
Little information was available about which outcomes were pri-
mary outcomes and how these were defined. The choice of pro-
gression outcome may be due to selective outcome reporting (see
below).
Other potential sources of bias
None identified.
Effects of interventions
See: Summary of findings for the main comparison Summary
of Findings Table
Primary outcome: Overall survival (OS)
All five trials of the main analysis with 1245 patients reported
OS. The addition of radiotherapy significantly improved OS (HR
= 0.40; 95% CI 0.27 to 0.61) with no evidence for heterogene-
ity between trials (I2 = 0%); Figure 3. In three trials the haz-
ard ratios had to be based on the survival curves or reported
dates of deaths (CALGB 7751; EORTC-GELA H9-F; Mexico
B2H031). In all cases, constant censoring was assumed as de-
scribed by Tierney 2007.However, this assumption is problematic
for the EORTC-GELA H9-F trial because the no-radiation arm
was closed early. Estimating a difference in censoring to account
for the premature closure of the chemotherapy alone arm had
only a minor effect on the hazard ratio calculated (Table 4 shows
HR of Mexico B2H031 and EORTC-GELA H9-F with different
censoring assumptions). Other uncertainties in the hazard ratio
calculation arose from P values with only one significant digit.
The results of the meta-analysis were dominated by the Mexico
B2H031 trial, which had a weight of 50.4% (Figure 3). When
excluding the Mexico B2H031 trial from the meta-analysis in a
sensitivity analysis, the summary hazard ratio remained statisti-
cally significant favouring CMT (0.57; 95% CI 0.33 to 0.98, I2
= 0%) (Figure 4). The substantial weight of the Mexico B2H031
trial was due to the higher number of observed deaths occurring
with longer follow-up. Here, patients had been followed up for
a median of 12 years as compared to two to seven years in the
other trials. The four-year survival rate of 83% in the Mexico
B2H031 trial was comparable to those of the other trials ranging
from 85% (MSKCC trial #90-44) to 87% (GATLA 9-H-77). No
information on the four-year survival was available from CALGB
7751. The EORTC-GELA H9-F trial included early favourable
patients in CR only and as a result had a higher five-year survival
rate of 97%. None of the subgroup analyses showed statistically
significant differences between the subgroups examined (type of
chemotherapy P = 0.14, early favourable or unfavourable disease
P = 0.31, bulky or no bulky disease P = 0.98, type (P = 0.20)
and timing (P = 0.76) of radiation therapy. See Figure 5, Figure 6,
Figure 7, Figure 8, Figure 9. Subgroup analyses by age or sex were
not possible due to the limited amount of data available. Subgroup
differences in performed sensitivity and subgroup analyses were
not statistically significant. The P values for subgroup differences
were P = 0.12 (length of follow-up Figure 10), P = 0.82 (four-
year overall survival in the chemotherapy group Figure 11), P =
0.56 (allocation concealment Figure 12), P = 0.56 (ITT-analysis
Figure 13). Due to the small number of trials included in themeta-
analysis true differences between subgroups may be missed in the
subgroup and sensitivity analyses.
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Figure 3. Forest plot of comparison: 1 Overall Survival, outcome: 1.1 All trials.
Figure 4. Forest plot of comparison: 1 Overall Survival, outcome: 1.11 Excluding the trial with highest
weight (Mexico B2H031).
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Figure 5. Forest plot of comparison: 1 Overall Survival, outcome: 1.2 Proportion of patients early
favourable.
Figure 6. Forest plot of comparison: 1 Overall Survival, outcome: 1.3 Bulky vs non-bulky.
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Figure 7. Forest plot of comparison: 1 Overall Survival, outcome: 1.4 Timing of radiotherapy.
Figure 8. Forest plot of comparison: 1 Overall Survival, outcome: 1.5 Type of radiotherapy.
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Figure 9. Forest plot of comparison: 1 Overall Survival, outcome: 1.6 Type of chemotherapy.
Figure 10. Forest plot of comparison: 1 Overall Survival, outcome: 1.7 Length of follow-up.
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Figure 11. Forest plot of comparison: 1 Overall Survival, outcome: 1.8 4 year survival in the CT group.
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Figure 12. Forest plot of comparison: 1 Overall Survival, outcome: 1.9 Allocation concealment.
Figure 13. Forest plot of comparison: 1 Overall Survival, outcome: 1.10 ITT-analysis.
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Table 4. Effects of censoring on estimates for overall survival hazard ratios calculated from survival curves
Censoring assumption Mexico B2H031 EORTC-GELA H9-F
Parmar Method without corrections 0.29 [0.17 to 0.51] 0.27 [0.04 to 1.74]
Parmar method with censoring *2 0.27 [0.16 to 0.48] 0.16 [0.02 to 1.49]
Parmar method with censoring *4 0.27 [0.15 to 0.48] 0.09 [0.01 to 1.67]
Parmar method with censoring *4, assum-
ing censoring began at the beginning of the
trial
0.27 [0.15 to 0.50] 0.09 [0.00 to 2.21]
Please note that using these methods censoring was assumed to be non-informative and constant. For the Mexico trial, even higher
censoring or assuming twice the amount of censoring in one of the groups had little effects on the HR. For the EORTC-GELA trial,
differences in censoring are expected between the two arms of the trial due to the early stopping of the arm without radiotherapy.
Estimating differences in median follow-up and incorporating them into the Parmar Method yielded a HR of 0.26 [0.05 to 1.72].
The sensitivity analysis that included trials not fulfilling the inclu-
sion criteria of our review protocol and including improper esti-
mates yields a HR of 0.60 (95% CI 0.35 to 1.03) with high het-
erogeneity (I² = 46%) Figure 14. When excluding the trials where
the number of cycles varies, the HR was 0.46 (0.27 to 0.78). The
two trials that examined chemotherapy plus radiotherapy versus
more chemotherapy reported conflicting results among the two
trials (Kung 2006; Meyer 2005). The trial by Meyer 2005 com-
paring two to four cycles of ABVD plus subtotal nodal irradiation
with six cycles of ABVD had an (estimated) HR of 1.73 (95% CI
0.62 to 4.86), while the Kung 2006 trial comparing four MOPP/
ABVD + IF-RT versus six MOPP/ABVD had an estimated HR
of 0.86 (95% CI 0.29 to 2.54).
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Figure 14. Overall Survival: Sensitivity analysis including additional trials. No early stage patients died in the
Nachman 2002 and the Picardi 2007 trial.
Numbers needed to treat to benefit have been calculated and are
presented in Table 5 based on the main analysis.
Table 5. Number Needed To Treat To Benefit
Outcome Assumed five-year survival in the control group NNT (95% confidence interval)
Tumour control 70% 6 (5 to 11)
Overall survival 85% 11 (9 to 18)
Overall survival 97% 55 (46 to 86)
2. Secondary outcomes
Tumour control
No trial reported progression-free survival (PFS) according to the
definition in the protocol (time to progression or death from any
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cause). However, four trials in the main analysis reported some
progression endpoint, such as event-free survival, time to treat-
ment failure and time to progression and were evaluated as tu-
mour control. Exact definitions are given in Table 3. Tumour con-
trol was statistically significant in three of the four trials in which
it was reported. The combination of chemotherapy and radio-
therapy improved tumour control with a hazard ratio (HR) of
0.41 (95% confidence interval (CI) 0.25 to 0.66, random-effects
model; Figure 15). There was clear statistical heterogeneity be-
tween trials (I2 = 68%) which may in part be due to the different
definitions used. For example, some trials examined progression
or freedom from treatment failure in all patients, while others ex-
amined disease free survival which is restricted to patients who
reached CR. A subgroup analysis by the type of tumour control
definition was statistically significant (P = 0.01; see Figure 16).
The subgroup by proportion of patients with early favourable dis-
ease was statistically significant (P = 0.01). However this result
is not plausible, as the group with a mixed patient population
showed less effect of the addition of radiotherapy and the two
groups with only early favourable and only early unfavourable pa-
tients were similar (Figure 17). The other subgroup and sensitivity
analyses showed neither statistically significant difference between
subgroups nor resulted in a relevant reduction of statistical het-
erogeneity. Factors analysed included type of chemotherapy (P =
0.10), early favourable versus unfavourable stages (P = 0.01), type
(P = 0.09) and timing (P = 0.57) of radiation, and the use of quality
measures (Figure 18, Figure 19, Figure 20, Figure 21, Figure 22,
Figure 23). The data extraction was hampered by discrepancies in
P values MSKCC trial #90-44 or number of patients included in
the analysisMSKCC trial #90-44, as well as by extraction of hazard
ratios from survival curves MSKCC trial #90-44; EORTC-GELA
H9-F.
Figure 15. Forest plot of comparison: 2 Progression-Free Survival, outcome: 2.1 All trials.
25Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 16. Forest plot of comparison: 2 Progression-Free Survival, outcome: 2.4 Definition of progression.
Figure 17. Forest plot of comparison: 2 Progression-Free Survival, outcome: 2.3 Proportion of patients
early favourable.
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Figure 18. Forest plot of comparison: 2 Progression-Free Survival, outcome: 2.2 Type of chemotherapy.
Figure 19. Forest plot of comparison: 2 Progression-Free Survival, outcome: 2.5 Timing of radiotherapy.
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Figure 20. Forest plot of comparison: 2 Progression-Free Survival, outcome: 2.6 Type of radiotherapy.
Figure 21. Forest plot of comparison: 2 Progression-Free Survival, outcome: 2.7 Length of follow-up.
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Figure 22. Forest plot of comparison: 2 Progression-Free Survival, outcome: 2.8 Allocation concealment.
Figure 23. Forest plot of comparison: 2 Progression-Free Survival, outcome: 2.9 ITT-Analysis.
All of the trials that did not meet the strict inclusion criteria of
our review protocol favoured combined modality treatment with
respect to tumour control (Kung 2006; Laskar 2004;Meyer 2005;
Nachman 2002; O’Dwyer 1984; Picardi 2007). When including
these trials into a meta-analysis for tumour control the HR was
0.38, 95% CI 0.28 to 0.57 (Figure 24).When restricting the anal-
ysis to the trials that kept the number of cycles the same between
the group that received radiotherapy and those that did not (with-
out Kung 2006 andMeyer 2005), the HR was 0.39 (95% CI 0.27
to 0.55). Repeating these analyses without the improper estimates
(without Nachman 2002 and Picardi 2007) yields a HR of 0.40
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(0.28 to 0.56) for the full group and 0.42 (0.28 to 0.63) for the
analysis without Kung 2006 and Meyer 2005.
Figure 24. Tumour Control: Sensitivity analysis including additional trials. Note: improper estimates based
on the number of events and the number in each group were used for the estimates of the Nachman trial and
the Picardi trial. The hazard ratio without the improper estimates is 0.40 (0.28 to 0.56)
Numbers needed to treat to benefit have been calculated and are
presented in Table 5 based on the main analysis.
Complete response (CR)
Four trials including 653 patients reported the CR rate and were
meta-analysed (CALGB7751;GATLA9-H-77;MexicoB2H031;
MSKCC trial #90-44). No evidence of an improvement in CR in
favour of CMTgroupwas found (RR: 1.07; 95%CI 0.98 to 1.17),
using a random-effects analysis due to substantial heterogeneity
(P value of the homogeneity test = 0.07; I² = 57%) (Figure 25).
Subgroup analyses by chemotherapy regimen (P for subgroup dif-
ferences = 0.10), evaluable patients (P = 0.07) and ITT-analysis (P
= 0.07) were performed (Figure 26, Figure 27, Figure 28). When
examining only those trials with less than 10% non-evaluable pa-
tients, the result had borderline significance (HR = 1.06; 95% CI
1.00 to 1.12) with moderate heterogeneity (I² = 20%) (Figure 28).
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For CR rates the sensitivity analysis including the additional trials
was not performed.
Figure 25. Forest plot of comparison: 3 Complete Response Rate, outcome: 3.1 All trials.
Figure 26. Forest plot of comparison: 3 Complete Response Rate, outcome: 3.2 Type of Chemotherapy.
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Figure 27. Forest plot of comparison: 3 Complete Response Rate, outcome: 3.3 ITT-analysis.
Figure 28. Forest plot of comparison: 3 Complete Response Rate, outcome: 3.4 Number of evaluable
patients.
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Overall response rate (ORR)
A total of 616 patients from 3 trials (GATLA 9-H-77; Mexico
B2H031; MSKCC trial #90-44) were included in the meta-anal-
ysis, of which 310 patients were in the CT-alone group and 306
patients in theCMT group.We found no evidence of a statistically
significant difference regarding ORR between the CMT group
and the CT-alone group (RR: 1.00; 95% CI 0.96 to1.06), with a
fixed-effect analysis. We found no evidence of heterogeneity across
the trials in the meta-analysis (P value of the homogeneity test =
0.68; I² = 0%) (Figure 29).
Figure 29. Forest plot of comparison: 4 Overall Response Rate, outcome: 4.1 All Trials.
Adverse events
Adverse events, both long term toxicities and acute toxicities are
tabulated in Table 6. All adverse events reported in the trials of the
main analysis are in the table. Certain adverse events considered of
particular interest (secondary malignancies, fertility, cardiac dis-
ease) but not reported are also listed. Most adverse events seem to
be similar in both groups and are typical for the chemotherapy re-
ceived (e.g. haematological effects, infections, bleomycin induced
lung disease).
Table 6. Adverse Events
CALGB 7751 EORTC-GELA
H9-F
GATLA 9-H-77 Mexico B2H031 MSCKK trial #90-
44
Number of patients
evaluated
18: CT
19: CmT
130: CT
448: CmT
142: CT
135: CmT
99: CT
102: CMT
76: CT
76: CMT
Chemotherapy and
radiotherapy
6 cycles of CVPP +/
- involved-field ra-
diotherapy (dosage
unknown)
6 cycles of EBVP +/
- IF RT
6 cycles of CVPP +/
- IF-RT
6 cycles of ABVD +/
- EF-RT
6 cycles of ABVD +/
- EF or IF RT
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Table 6. Adverse Events (Continued)
Median duration of
follow-up
1.8 years 4.3 years 4 years 11.4 years 5.6 years
Leukopenia or neu-
tropenia
NR NR “mild” in both
groups
CT: 12%
CMT 14%
CT grade I-II: 31
(31%); grade III-IV:
7 (7%)
CMT grade I-II: 39
(39%); grade III-IV
24 (22%)
Leukope-
nia: 27 (18%) de-
veloped grade II-IV
leukopenia
12 patients hospi-
talised for neutrope-
nia (8%)
After
a protocol amend-
ment 1992 to allow
the use of prophy-
lactic filgrastim, up
to 62% of patients
received filgrastim
Infections and in-
fection-related mor-
tality
NR NR CT: 1 patient died
of sepsis
CMT: 2 patients
died of sepsis
no febrile neutrope-
nia was observed
1 patient died of
sepsis and pneumo-
nia in the context of
neutropenia
Thrombopenia NR NR NR CT: 2 (2%)
CMT: 5 (4%)
Grades I-II
Grade
4 thrombopenia in 3
patients (2%)
Anaemia NR NR NR NR Grade 3 decrease in
haemoglobin in 5
patients (3%), grade
4 decrease in 2 pa-
tients (1%)
Neurotoxicity NR NR “no severe case was
reported”
CT: grade I-II 24
(24%)
CMT grade I-II 36
(35%); grade III-IV
3 (3%)
NR
Alopecia NR NR “mild” CT: 34 (34%)
CMT: 29 (28%)
Grade III-IV
CT: 13 (13%)
CMT: 8 (8%)
NR
Nausea and Vomit-
ing
NR NR “mild” CT grade I-II: 46
(46%)
CMT grade I-II: 63
Grade 3 nausea in
15 patients (10%)
Grade 3 emesis in 7
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Table 6. Adverse Events (Continued)
(61%) patients (5%)
Lung fibrosis NR NR NR 0 patients 33 pa-
tients (22%) (18 pa-
tients ABVD+RT,
15 ABVD-
alone) discontinued
bleomycin due to an
in-
crease of more than
20% in the DLCO
(diffusion lung ca-
pacity) test; 10 pa-
tients were treated
with glycocor-
ticoids. None devel-
oped chronic symp-
tomatic pulmonary
disease. One patient
died of bleomycin
induced toxicity.
Secondary
malignancy
NR 1 patient died of
AML (number of
secondary
malignancies not re-
ported)
One patient in the
CT group devel-
oped bladder can-
cer.
CT: 2 patients de-
veloped malignant
lymphoma 3.6; 6.4
years after comple-
tion of treatment
(both alive at the
end of study)
CMT: 2 patients
had MDS and sub-
sequent acute
leukaemia.
They died 3.1 and
9.5 years after com-
pletion of therapy
CT: 2 patients with
secondary ma-
lignancies observed
(gastric carcinoma,
2 non-fatal skin can-
cers in one patient)
CMT: 5 secondary
malignancies:
3 prior to RT: fol-
licular thyroid car-
cinoma, 2 patients
with follicular B-cell
non-Hodgkin´ s
lymphoma; 2 after
RT: one papillary
thyroid carcinoma,
one parotid carci-
noma
Infertility NR NR NR NR NR
Cardiac disease 1 patient in the
CMT group died of
a heart attack during
chemotherapy
NR NR NR NR
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D I S C U S S I O N
The following findings emerge from this meta-analysis:
1. In patients with early stage HL, there is no evidence that
the complete response rate is different in patients receiving che-
motherapy alone compared to those receiving combined modality
treatment (CMT) consisting of chemotherapy plus radiotherapy.
2. Tumour control is better in patients receivingCMTcompared
to chemotherapy alone.
3. Adding radiotherapy to chemotherapy improves overall
survival in this group of patients.
To our knowledge this is the first comprehensive review focusing
on patients with early stage Hodgkin lymphoma that compares
chemotherapy alone with CMT consisting of chemotherapy plus
additional radiotherapy. The main analysis according to the strict
inclusion criteria of our review protocol included five randomised
controlled trials with 1245 patients of both early favourable and
early unfavourable Hodgkin lymphoma. The literature search re-
vealed a number of trials with more than 20% of patients in ad-
vanced stages or with fewer cycles of chemotherapy in patients
receiving radiotherapy. Because these trials were considered to be
relevant to the underlying clinical question, these trials were in-
cluded in sensitivity analyses, where subgroup information of early
stage patients was used if available. These sensitivity analyses un-
derlined the results of the main analyses.
The hazard ratio for overall survival (0.40; 95% CI 0.27 to 0.61)
is similar to that of tumour control. With an assumed OS of 85%
at five years as observed in the three trials included here (GATLA
9-H-77; Mexico B2H031; MSKCC trial #90-44), approximately
11 patients (95% CI 9 to 18) would require treatment with CMT
for one additional patient to survive during the first five years.
With better survival (97.5%) as reported in the EORTC-GELA
H9-F trial, approximately 55 patients (95% CI 46 to 86) would
be needed. (For other numbers needed to treat to benefit see Table
5). These potentially surprising results were robust when exclud-
ing the Mexico B2H031 trial, which had a high weight in the
analysis due to the long period of follow-up and the relatively high
mortality. The only concern in the overall survival analyses stems
fromhazard ratios estimated from survival curves (EORTC-GELA
H9-F; Mexico B2H031) and the use of preliminary data from the
EORTC-GELA H9-F trial. However, these are minor points, as
the direction of the effect is clear and only themagnitude may vary
slightly. Again, the sensitivity analysis including additional trials
(Kung 2006; Laskar 2004;Meyer 2005;Nachman 2002; O’Dwyer
1985; Picardi 2007) also supported the results in favour of CMT.
Two additional trials had effect estimates favouring CMT, two tri-
als observed no deaths (Nachman 2002; Picardi 2007) and two
trials observed a slight effect favouring chemotherapy alone, which
was not statistically significant. One of these trials is a very small,
very old trial using MOPP chemotherapy (O’Dwyer 1985). The
other trial Meyer 2005, similar to the trial by Kung 2006 replaced
two to four cycles of ABVD chemotherapy with subtotal nodal
irradiation. They are therefore not directly comparable to the trials
which used the same number of cycles in both arms of the trials,
nor to trials examining smaller radiation fields.
In the present analyses we found no evidence for interaction of
treatment options or patient characteristics. Two of five trials em-
ployed ABVD, and the summary hazard ratios in the subgroup
analyses by chemotherapy regimen were very similar. No differ-
ence in tumour control or OS was observed between trials that
examined the addition of involved field or extended field radio-
therapy. This is in line with the finding that extended field radio-
therapy had little or no advantage over involved field radiotherapy
in Hodgkin patients when used alone or after effective chemo-
therapy (Engert 2003; Franklin 2005; Specht 1998). In addition,
subgroup analyses gave no hint that the hazard ratios may differ
depending on the proportion of patients with early favourable or
early unfavourable disease or the inclusion or exclusion of patients
with bulky disease. However, due to the small number of trials
included, obtaining reliable information from subgroup analyses
is unlikely.
Long term adverse effects such as secondary malignancies or car-
diac disease are important in HL patients and can occur later than
the reported observation times of the discussed trials. Radiother-
apy can induce secondary malignancies while the exact increase
in the risk is unclear. The absolute risk difference between che-
motherapy alone and chemotherapy plus radiotherapy in a recent
individual patient data meta-analysis was about 1% in early stage
patients at 15 years (Franklin 2005). Some cohorts of Hodgkin
patients of any stage suggest that this difference may be higher
(Bhatia 2003; Dores 2002; Swerdlow 2003; van Leeuwen 2000).
Unfortunately, the results of these cohorts are mixed and far from
clear (see Table 7). In addition, patients who relapse have a more
pronounced risk of secondary malignancies according to a cohort
study by Aleman 2003. Therefore the addition of radiotherapy
which reduces the number of patients with relapse (who require
more aggressive therapy) may contribute to a smaller overall risk
difference than suggested by the cohorts who do not distinguish
between relapsed an non-relapsed patients when evaluating the
risk of radiotherapy.
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Table 7. Risk of secondary malignancies in cohorts of patients with Hodgkin lymphoma
Cohort Comparison Measure Results notes
Dores 2002 any radiotherapy vs. che-
motherapy alone
observed divided by ex-
pected (O/E)
1 to 9 years after treat-
ment: 488 RT and 221
CTpts: O/E 2.3 (RT) and
2.3 (CT);
10 to 14 years: 206 and
48 pts; 3.2 (RT) and 2.6
(CT);
15 to 19 years: 132 RT
and 14 CT pts O/E: 3.5
(RT) and 1.7 (CT)
no stage information
van Leeuwen 2000 initial CT+ RT (first year)
and initial CT alone
Relative risk compared
to general population by
type of cancer
CT-alone: 75 pts; CT +
RT: 234 pts
breast cancer:
CT-alone:
(no cases)
CT + RT as initial ther-
apy: 7.5 (2.7 to 16.3)
All solid tumours except
breast:
CT-alone:
1.3 (0.03 to 7.4)
CT + RT as initial ther-
apy: 4.4 (2.0 to 8.3)
adolescence and
early adulthood; no stage
information; no informa-
tion about the length of
follow-up in each group
Swerdlow 2000 final treatment received standardized incidence ra-
tio (SIR) compared to the
general population by age
of first treatment
Chemotherapy alone:
age 25 to 44: SIR = 4.0
(2.7 to 5.6); age 45 to 54:
SIR = 2.3 (1.4 to 3.4)
CT + RT:
age 25 to44SIR=4.2 (3.1
to 5.6);
age 45 to54SIR=3.8 (2.5
to 5.4)
no stage information
Bhatia 2003 final treatment received % of pts with secondary
malignancies
Chemotherapy alone:
9.4% of 106 pts;
CT + RT:
12.7% of 960 pts.
no information on stage,
nor on original therapy,
nor duration of follow-up
Cardiac disease is associated with mediastinal radiation and with
the cumulative dose of chemotherapy, in particular doxorubicin
(Singal 1998). Radiation fields have been reduced substantially
from extended field radiotherapy to involved field or even involved
node radiotherapy used today. Replacing consolidation radiother-
apy with chemotherapy, as evaluated byMeyer 2005, increases the
dose of doxorubicin and may thus increase long term cardiac tox-
icity. Importantly, there was also a detrimental effect on progres-
sion-free survival in the group of patients receiving chemotherapy
only.
Identifyingpatients at low risk of relapsemight be considered an al-
ternative to consolidation radiotherapy for all patients. Currently,
however, no reliable evidence for such a strategy exists. In this
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meta-analysis, the presence of conventional CR after chemother-
apy such as ABVD (Mexico B2H031; MSKCC trial #90-44) or
EBVP (EORTC-GELA H9-F) does not seem to accurately iden-
tify a group of patients who do not benefit from radiotherapy with
regard to tumour control. PET may be an alternative. However in
patients with bulky early stage disease having residual masses in
CT that are PET negative, the rate of relapse after ABVD chemo-
therapy was much higher in patients who did not receive consoli-
dation radiotherapy (Picardi 2007). Two other trials are planed or
under way in patients with early stage Hodgkin lymphoma (clin-
icaltrials.gov identifiers: NCT00736320, NCT00433433).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Adding radiotherapy to a commonly used chemotherapy regimen
such as ABVD increases five-year overall survival and tumour con-
trol in patients with early stage Hodgkin lymphoma.
Implications for research
Since adding radiotherapy may result in more secondary malig-
nancies or cardiac disease and deaths thereof, long-term follow-up
(more than 15 years) of clinical trials examining treatment options
in early stage HLwould be helpful. In addition, clear definitions of
outcomes that examine tumour control would be useful in order
to reduce heterogeneity. We recommend the use of progression-
free survival, i.e. time to progression, relapse or death of any cause.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
CALGB 7751
Methods • Randomised controlled trial with two arms: CT-alone arm and CMT arm.
• Conducted by the Cancer and Leukemia Group B (CALGB), USA.
• Recruitment period in 1970s, exact period unclear.
• 55 patients allocated; exact number per arm not reported.
• 37 patients evaluated: 18 patients in CT-alone arm and 19 patients in CMT arm.
• Baseline patient’s characteristics described.
• Median follow-up time: 22 months.
• Not ITT analysis; more than 10% of the enrolled patients not evaluated.
Participants • Inclusion criteria: patients with histologically documented, previously untreated,
poor prognosis pathological stage I and I; poor prognosis was defined as symptom class
B, mixed cellularity or lymphocyte depleted histology, a large mediastinal mass, or age
> 40 years
• Exclusion criteria: not reported.
• PS I, II: CT-alone: 1, 17; CMT: 6, 13.
• Prognostic features: not reported.
• Mean age: CT-alone: 24 years; CMT: 30 years;
• Gender male, female: CT-alone: 6, 12; CMT: 14; 5.
• Baseline patient’s characteristics: more male patients in CMT arm; more patients
with mediastinal mass in CT-alone arm.
• Histopathologic diagnosis: according to Rye modification of Lukes and Butler
classification.
Interventions • CT-alone: 6 cycles of CVPP (cyclophosphamide (75 mg/m² orally, day 1),
vinblastine (4mg/m² intravenous, days 1 and 8), procarbazine (100 mg/m² orally, days
1-14), prednisone (40 mg/m² orally, days 1-14)); repeated every 14 days.
• CMT: same CT with involved-field radiotherapy; dose of radiotherapy (RT) not
reported; RT delivered before CT.
• No additional treatment.
Outcomes • Overall survival reported.
• Complete response reported.
• Partial response not reported.
• Progression-free survival not reported.
Notes • Response documented after two cycles of CT.
• Source of funding not reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “randomly allocated”
Allocation concealment? Unclear Not reported.
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CALGB 7751 (Continued)
Blinding?
Overall survival
Yes Patients not blinded. No information
about blinding of the assessor. This is
judged not to be a source of bias for overall
survival.
Blinding?
Other outcomes
Unclear Patients not blinded. No information
about blinding of the assessor.
Incomplete outcome data addressed?
All outcomes
No 22 months OS and response outcome: 18/
55 missing from the outcome analysis; no
information per study arm. This trial was
considered not to have performed an ITT
analysis in the subgroup analysis.
Free of selective reporting? Unclear Dates of relapse and deaths are given. Dates
of progression not given nor information
about censoring. No time to event out-
comes calculated.
Free of other bias? Unclear Very little information in the report.
EORTC-GELA H9-F
Methods • A randomised controlled trial with three arms: comparison of three radiation
dosis; 36 Gy involved-field radiotherapy, 20 Gy involved-field radiotherapy and no
radiotherapy in patients that achieved complete response (CR) after six cycles of EBVP.
• Conducted by EORTC (European Organization for Research and Treatment of
Cancer) and GELA (Groupe d’Etude des Lymphomes de l’Adulte); 111 institutions
from 10 European countries involved.
• Recruitment period from September 1998 to May 2004.
• 784 patients enrolled.
• 13 patients not evaluable before randomisation (6 refusals, 3 protocol violations,
4 unspecified).
• 578 patients randomised to three radiation doses.
• 578 patients evaluated.
• Baseline patient’s characteristics not reported (abstract publication).
• Median follow-up 51 months (range 14 to 81).
• ITT analysis.
Participants • Inclusion criteria: adult patients with supradiaphragmatic CS I-II Hodgkin
lymphoma and favourable features (age < 50, CS I-II, symptoms class A + ESR < 50 or
symptoms class B + ESR < 30 and MT ratio < 0.35).
• Exclusion criteria: not reported.
• Age: 31 (15 to 49)
• Gender: 55% male; 45% female
• CS: patients with CS I-II without bulky disease.
• Prognostic features: all included patients with favourable risk factors.
• Histopathologic diagnosis: not reported.
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EORTC-GELA H9-F (Continued)
Interventions • CT-alone: 6 cycles of EBVP (epirubicin (70 mg/m² intravenous, day 1),
bleomycin (10 mg/m² intravenous/intramuscular, day 1), vinblastine (6 mg/m²
intravenous, day 1), prednisone (40 mg/m² orally, day 1-5)); repeated after every 21
days.
• CMT: same CT before randomisation with 36 Gy involved-field radiotherapy or
20 Gy involved-field radiotherapy.
• No additional treatment.
Outcomes • Overall survival reported; observation time 4 years.
• Response not reported.
• Progression-free survival not reported.
• Disease-free survival reported (Table 3).
Notes • Inclusion of patients in no radiotherapy arm was stopped in May 2002 because
stopping rules were met that is > 20% events occurred.
• Hazard ratio estimate is based on the full group receiving additional radiotherapy
and not only those patients up to the time the no radiotherapy arm was stopped.
• Source of funding not reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Patients were randomly allocated. No fur-
ther information available. However it was
a large multicenter trial with presumably
central allocation (older trials of the same
group). We therefore assume that it was
probably ok.
Allocation concealment? Yes No information available from the publi-
cations. However, it is a large multicenter
trial with 120 centres.Older trials from this
group were centrally allocated. We there-
fore assume that it was probably ok.
Blinding?
Overall survival
Yes Patients not blinded (not expected due to
the treatment with radiotherapy). No in-
formation about blinding of the assessor.
This is judged not to be a source of bias for
overall survival.
Blinding?
Other outcomes
Unclear Patients and physicians not blinded (not
expected due to the treatment with radio-
therapy). No information about blinding
of the assessor.
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EORTC-GELA H9-F (Continued)
Incomplete outcome data addressed?
All outcomes
Yes No withdrawals and protocol violations af-
ter randomisation reported. Analysis was
performedon ITTbasis and all randomised
patients were included in the analysis.
Free of selective reporting? Yes Rationale for the use of disease-free survival
not described. However all patients are in
CR at the time of randomisation. Disease-
free survival should therefore be equivalent
to progression free survival. Other progres-
sion outcomes that are more prone to bias
are not used and not reported. Despite no
protocol being available, we judge that the
trial is free of selective outcome reporting.
Free of other bias? No Trial was ended early due to predefined
stopping rule. This is known to increase the
effect estimate of trials. In addition the data
are preliminary.
GATLA 9-H-77
Methods • A randomised controlled trial with two arms: CT-alone arm and CMT arm.
• Conducted by Group Argentino de Tratamientode la Leucemia Aguda (GATLA).
• Recruitment period from September 1977 to October 1986.
• 293 patients randomised: CT-alone:148; CMT: 145.
• 277 patents evaluated: 142 in CT-alone arm and 135 in CMT arm.
• 16 patients not evaluated; 4 drop outs and 2 protocol violations in CT-alone arm;
9 drop outs and one protocol violation in CMT arm.
• Baseline patient’s characteristics described.
• Median time on study was 43 months for CT-alone arm and 51 months for
CMT arm.
• Not ITT analysis; less than 10% of enrolled patients not evaluated.
Participants • Inclusion criteria: patients with pathologically proven Hodgkin lymphoma,
according to Lukes and Butler’s criteria.
• Exclusion criteria: patients with CS III.
• CS I, II: CT-alone: 47, 95; CMT: 46, 89; overall CS I 93, CS II 184.
• Prognostic features: CT-alone: 82 patients with early favourable stage; 60 patients
with early unfavourable stage; CMT: 91 patients with early favourable stage; 44
patients with early unfavourable stage.
• Age: patients of all ages; median age not reported; 124 patients (45%) were
children < 16 years.
• Gender: CT-alone: 87 males, 55 females; CMT: 88 males, 47 females.
• Similar baseline patient’s characteristics in comparison arms.
• Histopathologic diagnosis: according to the Rye modification of the Lukes and
Butler.
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Interventions • CT-alone: 6 monthly cycles of CVPP (cyclophosphamide (600 mg/m²
intravenous, day 1), vinblastine (6 mg/m² intravenous, day 1), procarbazine (100 mg/
m² orally, days 1-14), prednisone (40 mg/m² orally, days 1-14)).
• CMT: same CT with IF-RT between third and fourth cycle of CT (sandwich
technique); dose of RT was 3000 rad.
• No additional treatment.
Outcomes • Overall survival reported also for prognostic groups; observation time 7 years.
• Complete response reported.
• Partial response reported.
• Progression-free survival not reported.
• “Disease-free survival” reported (see Table 3)
Notes • Limited overall survival data for prognostic groups; estimation of HR not possible.
• Academic funding.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “[...] patients [...] were randomised [...] ”
No further information available.
Allocation concealment? Unclear No information available.
Blinding?
Overall survival
Yes Patients not blinded. No information
about blinding of the assessor. This is
judged not to be a source of bias for overall
survival.
Blinding?
Other outcomes
Unclear Patients not blinded. No information
about blinding of the assessor.
Incomplete outcome data addressed?
All outcomes
Yes 5 years OS and response rate: 6/142 miss-
ing from CT-alone arm and 10/135 from
CMT arm; 13 lost to follow-up before
completing 6 cycles and 3 protocol viola-
tions (not described in detail);
Therefore for subgroup analysis this trial
was considered not to have performed an
ITT analysis.
Despite the authors not addressing the
missing outcomes in analyses, we judge that
these few missing data have very little in-
fluence on the overall results.
Free of selective reporting? Unclear For progression outcome, disease-free sur-
vival was chosen.No other progression out-
comes are reported but it is unclearwhy dis-
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ease-free survival was chosen and not pro-
gression free survival. No protocol is avail-
able.
Free of other bias? Yes From the report, the trial seems free of other
bias.
Mexico B2H031
Methods • Randomised controlled trial with three arms: CT-alone arm, CMT arm and RT-
alone arm.
• Conducted at Oncology Hospital, National Medical Center, Mexico.
• Recruitment period from 1983 to 1988.
• 327 patients enrolled.
• 307 patients evaluated; 99 patients in CT-alone arm; 102 patients in CMT arm
and 106 patients in RT-alone arm.
• 20 patients not evaluated due to advanced stage and infradiaphragmatic
involvement.
• Baseline patient characteristics described.
• Median follow-up time 11.4 years (range 6.3 - 16.5 years).
• Not ITT analysis; less than 10% of enrolled patients not evaluated.
Participants • Inclusion criteria: both male and female adult patients with clinical stage I and II
(CS I and II), supradiaphragmatic disease and the presence of bulky disease.
• Exclusion criteria: patients with advanced stages and infradiaphragmatic
involvement.
• CS I, II: CT-alone: 21, 78; CMT: 22, 80; overall CS I 34%, CS II 66%.
• Prognostic features not reported.
• Mean age (range): CT-alone: 39 (20 to 70) years; CMT: 42 (18 to 71) years.
• Gender: CT-alone: 40 males, 59 females; CMT: 51 males, 51 females.
• Similar baseline patient’s characteristics in comparison arms.
• Histopathologic diagnosis: according to Rye modification of Lukes and Butler
classification.
Interventions • CT-alone: 6 monthly cycles of ABVD (adriamycin, bleomycin, vinblastine,
dacarbazine); dose not reported.
• CMT: same CT with mantle-field radiotherapy (MF-RT) between third and
fourth cycles of CT (sandwich technique); dose of RT: 3500-3800 cGy in fraction of
200-250 cGy four to five times a week for four to six weeks.
• RT-alone: EF-RT with a dose of 3500-3800 cGy in fraction of 200-250 cGy four
to five times a week over a period of four weeks; 106 patients from this arm not
included in the review.
• No additional treatment.
Outcomes • Overall survival reported; observation time 12 years.
• Complete response reported.
• Partial response reported.
• Progression-free survival not reported.
• Contradictory definitions of disease-free survival (see Table 3)
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Notes • Source of funding not reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “a prospective randomised trial”No further
information available.
Allocation concealment? Unclear No information available.
Blinding?
Overall survival
Yes Patients not blinded. No information
about blinding of the assessor. This is
judged not to be a source of bias for overall
survival.
Blinding?
Other outcomes
Unclear Patients and physicians not blinded. No in-
formation about blinding of the assessor.
Incomplete outcome data addressed?
All outcomes
Unclear 12 years OS and tumour control outcome:
20/327 missing from the outcome analysis;
no information per study arm. The authors
do not give any further information about
the method of analysis (e.g. intention-to-
treat)
We do not believe that these few missing
patients induced large bias in the analysis,
but because the information is not available
by study arm and it remained unclear in
which arm patients who did not receive ra-
diotherapy were evaluated, we judged un-
clear.
For subgroup analysis this trial was consid-
ered to have no ITT analysis.
Free of selective reporting? Unclear In the methods section: “Disease-free sur-
vival was calculated for CR patients from
the beginning of treatment until clinical
or radiological and biopsy proven relapse.”
No information about patients that did not
achieve CR. However, the denominator in
the results section is the full population, not
only patients in CR. Both disease-free sur-
vival and relapse free survival were calcu-
lated but only disease free survival was re-
ported.Due to the information given about
toxic deaths, overall survival and disease-
free survival, we assume that relapse free
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survival would also have been statistically
significant and possibly similar to disease-
free survival, thus not resulting in any bias.
In addition, disease-free survival is prefer-
able to relapse free survival as it includes
deaths. For these reasons, we choose “un-
clear” and not “no”. There is no infor-
mation about progression free survival. A
study protocol was not available.
Free of other bias? Yes No reason to suspect other sources of bias.
MSKCC trial #90-44
Methods • A randomised controlled with two arms: CT-alone arm and CMT arm.
• Conducted by MSKCC (Memorial Sloan-Kettering Cancer Center), USA.
• Recruitment period from May 1990 to June 2000.
• 152 patients randomised.
• 152 patients evaluated for OS; 138 patients evaluated for response rate.
• 14 patients not evaluated for response outcome.
• Baseline patient’s characteristics described.
• Median follow-up time 67 months (range 1 to 125 months).
• ITT analysis for overall survival; not ITT analysis for response outcomes.
Participants • Inclusion criteria: patients with a confirmed diagnosis of Hodgkin lymphoma,
without previous treatment and with clinical or pathological stage IA, IIA, IIB or IIIA
and lack of bulky nodal tumour (mediastinal mass ≤ 0.33, the thoracic diameter on
chest x-ray measured at T11, and/or peripheral or retroperitoneal adenopathy ≤ 10 cm
in its largest diameter).
• Exclusion criteria: patients with chronic lung disease with a diffusing capacity of
less than 60% and/or with cardiac disease with clinical congestive heart failure or an
abnormal ventricular ejection fraction (< 50%) on echocardiogram or multiple gated
acquisition scan were excluded.
• CS I, II: CT-alone: 19, 46; CMT: 9, 58.
• CS III: CT-alone: 11; CMT: 9.
• Prognostic features not reported.
• Median age: CT-alone: 33 years (range 16-68 years); CMT: 39 years (range 15-66
years).
• Gender: 87 males, 65 females.
• Small imbalance in the distribution of sex, stage and histology, regarding baseline
patient’s characteristics in comparison arms.
• Histopathologic diagnosis: according to the Rye modification of the Lukes and
Butler classification.
Interventions • CT-alone: 6 cycles of ABVD (doxorubicin (25 mg/m²), bleomycin (10 units/m²),
vinblastine (6 mg/m²), dacarbazine (375 mg/m² intravenously, days1 and 15));
repeated after every 28 days.
• CMT: same CT with extended-field radiotherapy (EF-RT) or involved-field
radiotherapy (IF-RT); dose of RT 36 Gy in 180 cGY daily fractions starting after 4-6
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weeks after completion of CT.
• Additional intervention: filgrastim was used for subsequent treatment of
neutropenic patients.
Outcomes • Overall survival reported; observation time 5 years.
• Complete response reported.
• Partial response reported.
• Progression-free survival not reported.
• Time to progression reported (see Table 3).
Notes • 13% patients with CS IIIA.
• Academic funding.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Sequence generation was not reported.
“Randomisation was performed after a
check for eligibility. Patients were stratified
according to clinical stage (IA or IIa, IIIA,
I B or IIB).”
Presumably the randomisation was ade-
quate.
Allocation concealment? Yes “Patients were enrolled by telephone call or
fax to the MSKCC Clinical Trials Office”
Blinding?
Overall survival
Yes Patients and physicians not blinded. No in-
formation about blinding of the assessor.
This is judged not to be a source of bias for
overall survival.
Blinding?
Other outcomes
Unclear Patients and physicians not blinded. No in-
formation about blinding of the assessor.
Incomplete outcome data addressed?
All outcomes
Yes 11 patients randomised to RT never re-
ceived RT: 6 refused, 4 progressed on che-
motherapy prior to receiving RT, 1 never
received RT because of bleomycin induced
toxicity to RT.
OS: all patients included in the analysis,
ITT-analysis
Tumour control: all patients included in
the analysis, ITT-analysis
Response rates: 7/76 excluded from CT-
alone arm and 7/76 excluded from CMT
arm; three lost to follow-up before comple-
tion of six cycles of chemotherapy and 11
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stage IA patients with no measurable dis-
ease prior to treatment.
Free of selective reporting? Unclear Choice of progression outcome not de-
scribed - both disease-free survival and free-
dom from progression evaluated; freedom
from progression was closer to our defini-
tion of PFS and was thus used in the anal-
yses.
Free of other bias? Yes No other bias identified.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andrieu 1999 Comparison arms not treated with CT-alone or CMT; all included patients received CMT.
Less than 80% of the participants had early stage Hodgkin lymphoma; only 25% of the included patients had
early stage Hodgkin lymphoma
Bonnet 2007 Less than 80% of the participants had early stage Hodgkin lymphoma; only 6 of the 576 included patients
had Hodgkin lymphoma.
Brusamolino 1994 Comparison arms not treated with CT-alone or CMT; compared interventions RT-alone versus CMT.
Cheveresan 1998 Comparison arms not treated with CT-alone or CMT; all included patients received CMT.
Cimino 1990 Not a randomised controlled trial; a review article.
Cosset 1992 Not a randomised controlled trial; a review article.
Desablens 1999 Comparison arms not treated with CT-alone or CMT; all patients received CMT.
Dionet 1988 Comparison arms not treated with CT-alone or CMT and different CT regimens used in comparison arms.
Hirsch 1996 Evaluation of pulmonary symptoms in patients randomised to MSKCC trials 1989 to 1993.
Not a report of one specific trial
Relevant patients presumably analysed in MSKCC trial #90-44 (recruitment 1990-2000)
Only 45 patients with the relevant comparison included
30: 6 X ABVD
15: 6 X ABVD plus EF RT
No mortality data given
Adverse events included only pulmonary function and included 15 patients not in the relevant randomised
comparison.
During CT 53% of patients had symptoms of cough or dyspnoea on exertion
At the end of follow-up (~ 1 year after treatment), 18% (CT) vs. 30% (CMT) reported persistent symptoms
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(P = 0.36)
Horning 1996 Less than 80% of the participants had early stage Hodgkin lymphoma; only 42% of the included patients had
early stage Hodgkin lymphoma.
Horning 2007 Comparison arms not treated with CT-alone or CMT; compared interventions RT-alone versus CMT.
Kim 2003 Not a randomised controlled trial; a retrospective data analysis of patients’ records with Hodgkin lymphoma.
Koerholz 2004 Not a randomised controlled trial.
Kung 1993 Less than 80% of the participants had early stage Hodgkin lymphoma; 69% of the included patients had early
stage Hodgkin lymphoma. No subgroup information available. (See also Kung 2006).
Kung 2006 Less than 80% of the participants had early stage Hodgkin lymphoma; 69% of the included patients had early
stage Hodgkin lymphoma. No subgroup information available.
Laskar 2004 Less than 80% of the participants had early stage Hodgkin lymphoma; 55% of the included patients had early
stage Hodgkin lymphoma.
Longo 1992 Not a randomised controlled trial; a review article about the trials (GATLA 9-H-77; O’Dwyer 1985).
Meyer 2005 Chemotherapy differed between treatment arms (2 cycles of ABVD+RT vs. 4-6 cycles of ABVD)
Nachman 2002 Less than 80% of the participants had early stage Hodgkin lymphoma; 55% of the included patients had early
stage Hodgkin lymphoma.
Noordijk 2006 Comparison arms not treated with CT-alone or CMT; compared interventions RT-alone versus CMT.
O’Dwyer 1984 Less than 80% of the participants with early stage Hodgkin lymphoma; 69% of the evaluable patients with
early stage Hodgkin lymphoma. Duplicate publication (see also O’ Dwyer 1985).
O’Dwyer 1985 Less than 80% of the participants had early stage Hodgkin lymphoma; 69% of the evaluable patients had
early stage Hodgkin lymphoma.
Pavlovsky 1997 Comparison arms not treated with CT-alone or CMT.
Picardi 2007 Less than 80% of the participants had early stage Hodgkin lymphoma; 66% of the included patients had early
stage Hodgkin lymphoma. No subgroup information available.
Radford 2002 Comparison arms not treated with CT-alone or CMT; compared interventions RT-alone versus CMT.
Rüffer 1996 Comparison arms not treated with CT-alone or CMT; compared interventions RT versus RT.
Rüffer 1998 Comparison arms not treated with CT-alone or CMT; all patients received CMT.
Rüffer 1999 Comparison arms not treated with CT-alone or CMT; all patients received CMT. Duplicate publication (see
also Ruffer 1998); all patients received CMT.
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Specht 1992 Not a randomised controlled trial; a review article.
Straus 1989 Comparison arms not treated with CT-alone or CMT; all patients received CMT.
Thistlethwaite 2007 Comparison arms not treated with CT-alone or CMT; compared interventions RT-alone versus CMT.
Characteristics of ongoing studies [ordered by study ID]
EORTC-GELA HD 10
Trial name or title Official title: The H10 EORTC/GELA Randomized Intergroup Trial on Early FDG-PET Scan Guided
Treatment Adaptation Versus Standard Combined Modality Treatment in Patients With Supradiaphragmatic
Stage I/II Hodgkin’s Lymphoma
Methods Randomised controlled trial
Participants • 15 Years to 70 Years
• DISEASE CHARACTERISTICS:
◦ Histologically confirmed Hodgkin’s lymphoma
◦ No nodular lymphocyte-predominant subtype (nodular paragranuloma)
◦ Supradiaphragmatic Ann Arbor clinical stage I or II disease
◦ Must meet criteria for 1 of the following prognostic subsets:
⋄ Unfavourable subset, defined as meeting 1 of the following criteria:
Clinical stage II disease with > 4 nodal areas involved
Mediastinum and hili are considered as 1 nodal area
Age > 50 years
Erythrocyte sedimentation rate (ESR) < 50 mm/hr with no B symptoms ESR < 30 mm/hr with B
symptomsMediastinum/thoracic (MT) ratio < 0.35
⋄ Favourable subset, defined as meeting all of the following criteria:
Clinical stage I disease OR stage II disease with < 3 involved areas
Age < 50 years
ESR < 50 mm/hr (no B symptoms) OR ESR < 30 mm/hr (B symptoms present)
MT ratio < 0.35
◦ Previously untreated disease
◦ Planning to undergo fludeoxyglucose F 18 positron emission tomography after the first 2 courses
of study chemotherapy
• PATIENT CHARACTERISTICS:WHO performance status 0-3
◦ Bilirubin < 2.5 times upper limit of normal (ULN)
◦ Creatinine < 2.5 times ULN
◦ Not pregnant or nursing
◦ Negative pregnancy test
◦ Fertile patients must use effective contraception
◦ No severe cardiac, pulmonary, neurologic, psychiatric, or metabolic disease
◦ No unstable diabetes mellitus
◦ No other malignancies within the past 5 years except for basal cell skin cancer or adequately
treated carcinoma in situ of the cervix
◦ No known HIV infection
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◦ No psychological, familial, sociological, or geographical condition that would preclude study
compliance
Interventions • Arm I (standard): Patients receive ABVD chemotherapy comprising doxorubicin hydrochloride IV,
bleomycin IV or intramuscularly (IM), vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment
repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with favourable
prognostic profile receive 3 courses of ABVD. Patients with unfavourable prognostic profile receive 4
courses of ABVD. Patients undergo FDG-PET scan after completion of 2 courses of ABVD. Beginning 3-4
weeks after completion of ABVD, patients undergo involved-node radiotherapy (INRT) 5 days a week for
4-6 weeks.
• Arm II (experimental): Patients receive ABVD as in arm I for 2 courses and then undergo FDG-PET
scan. Further treatment is adapted according to FDG-PET scan result.FDG-PET negative: Patients with
favourable prognostic profile receive 2 additional courses of ABVD. Patients with unfavourable prognostic
profile receive 4 additional courses of ABVD. FDG-PET positive: Patients receive escalated BEACOPP
chemotherapy comprising cyclophosphamide IV and doxorubicin hydrochloride IV on day 1, vincristine IV
and bleomycin IV or IM on day 8, etoposide IV on days 1-3, oral procarbazine hydrochloride on days 1-7,
oral prednisone on days 1-14, and filgrastim (G-CSF) subcutaneously beginning on day 9 and continuing
until blood count recover. Treatment repeats every 21 days for 2 courses in the absence of disease
progression or unacceptable toxicity. Beginning 3-4 weeks after completion of BEACOPP, patients undergo
INRT 5 days a week for 4-6 weeks.
Outcomes Primary Outcome Measures: Progression-free survival
Secondary OutcomeMeasures: Event-free survival; Overall survival; Long-term toxicity, in terms of secondary
malignancies, cardiovascular events, and pulmonary events; Response
Duration 10 years
Starting date October 2006
Contact information John Raemaekers, MD, PhD 31-24-361-4762 J.Raemaekers@hemat.umcn.nl
Notes NCT00433433, 1600 patients planned
Friedman
Trial name or title Official title: A phase III group-wide study of dose-intensive response-based chemotherapy and radiation
therapy for children and adolescents with newly diagnosed intermediate risk Hodgkin disease.
Methods A randomised controlled trials.
Initial CT to all patients with 2 cycles of ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, pred-
nisone, cyclophosphamide).
Patients with RER (rapid early response) that > 60% disease reduction receive 2 additional courses of ABVE-
PC.
Patients with complete response after 4 courses randomised to receive either RT or no further treatment.
Patients with SER (slow early response) that < 60% disease reduction: Arm I: 2 courses of DECC (dexam-
ethasone, etoposide, cytarabine, cisplatin) and 2 additional courses of ABVE-PC and RT; Arm II: Patients
with SER receive 2 additional courses of ABVE-PC without DECC and RT (Arm II). These patients are not
relevant for the review
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Participants Both male and female patients up to 21 years with newly diagnosed Hodgkin’s lymphoma without prior
therapy.
Interventions CT-alone: 4 cycles of ABVE-PC, repeated after every 21 days.
CMT: 4 cycles of ABVE-PC and RT
Outcomes Primary outcome measure: event-free survival.
Secondary outcome measures: overall survival; disease response; toxicity.
Starting date September 2002.
Contact information Investigator: Debra L. Friedman MD, Childrens Hospital and Regional Medical Center, Seattle. Childrens
Oncology Group, National Cancer Institute (NCI).
Notes The trial has been suspended (last accessed August 7th, 2009)
Final data collection date for primary outcome measure June 2010.
ClinicalTrials.gov Identifier: NCT00025259 (www.clinicaltrials.gov)
GHSG HD 16
Trial name or title Official Title: HD16 for Early Stages - Treatment Optimization Trial in the First-Line Treatment of Early
Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET
Methods Randomised controlled trial, non-inferiority design
Participants 18 Years to 75 Years
Inclusion Criteria:
• Hodgkin lymphoma
• CS I, II without any of the following risk factors: large mediastinal mass (> 1/3 of maximum transverse
thorax diameter)extranodal involvement elevated ESR3 or more involved nodal areas
• Written informed consent
Exclusion Criteria:
• Leucocytes < 3000/µl
• Platelets < 100000/µl
• Hodgkin lymphoma as composite lymphoma
• Activity index (WHO) > 2
Interventions Arm 1: 2 cycles ABVD followed by 30 Gy IF-RT irrespective of FDG-PET results after chemotherapy
Arm 2: 2 cycles ABVD followed by 30 Gy IF-RT if FDG-PET is positive after chemotherapy; 2 cycles ABVD
and treatment stop if FDG-PET is negative after chemotherapy
Outcomes Primary Outcome Measures: Progression Free Survival (Time Frame: 5 years)
Secondary Outcome Measures: Overall survival, acute and late toxicity, CR-rate (Time Frame: 5 years)
Starting date unclear
Contact information Michael Fuchs; GHSG@uk-koeln.de
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Notes clinicaltrials.gov identifier NCT00736320; 1100 patients to be enrolled
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D A T A A N D A N A L Y S E S
Comparison 1. Overall Survival
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All trials 5 1245 Hazard Ratio (Random, 95% CI) 0.40 [0.27, 0.61]
2 Excluding the trial with highest
weight (Aviles)
4 1044 Hazard Ratio (Random, 95% CI) 0.57 [0.33, 0.98]
3 Proportion of patients early
favourable
5 Hazard Ratio (Random, 95% CI) 0.40 [0.27, 0.61]
3.1 All patients early
favourable
1 Hazard Ratio (Random, 95% CI) 0.27 [0.04, 1.74]
3.2 ~ 1/3 to 1/2 patients early
unfavourable
2 Hazard Ratio (Random, 95% CI) 0.57 [0.28, 1.15]
3.3 All patients early
unfavourable
2 Hazard Ratio (Random, 95% CI) 0.31 [0.18, 0.54]
4 Bulky vs non-bulky 3 Hazard Ratio (Random, 95% CI) 0.29 [0.18, 0.48]
4.1 Bulky disease 1 Hazard Ratio (Random, 95% CI) 0.29 [0.17, 0.51]
4.2 Non-bulky disease 2 Hazard Ratio (Random, 95% CI) 0.30 [0.10, 0.87]
5 Timing of radiotherapy 5 Hazard Ratio (Random, 95% CI) 0.40 [0.27, 0.61]
5.1 Radiotherapy after
chemotherapy
2 Hazard Ratio (Random, 95% CI) 0.30 [0.10, 0.87]
5.2 Sandwich technique
(CT-RT-CT)
2 Hazard Ratio (Random, 95% CI) 0.44 [0.19, 1.04]
5.3 Chemotherapy after
radiotherapy
1 Hazard Ratio (Random, 95% CI) 0.63 [0.11, 3.65]
6 Type of radiotherapy 5 Hazard Ratio (Random, 95% CI) 0.40 [0.27, 0.61]
6.1 Involved field 3 Hazard Ratio (Random, 95% CI) 0.62 [0.33, 1.17]
6.2 Extended field 1 Hazard Ratio (Random, 95% CI) 0.29 [0.17, 0.51]
6.3 Mixed 1 Hazard Ratio (Random, 95% CI) 0.31 [0.08, 1.15]
7 Type of chemotherapy 5 Hazard Ratio (Random, 95% CI) 0.40 [0.27, 0.59]
7.1 ABVD 2 Hazard Ratio (Random, 95% CI) 0.30 [0.18, 0.50]
7.2 CVPP 2 Hazard Ratio (Random, 95% CI) 0.68 [0.35, 1.31]
7.3 EBVP 1 Hazard Ratio (Random, 95% CI) 0.27 [0.04, 1.73]
8 Length of follow-up 5 Hazard Ratio (Random, 95% CI) 0.40 [0.27, 0.61]
8.1 Six years or less 4 Hazard Ratio (Random, 95% CI) 0.55 [0.31, 0.96]
8.2 More than six years 1 Hazard Ratio (Random, 95% CI) 0.29 [0.17, 0.51]
9 4 year survival in the CT group 5 Hazard Ratio (Random, 95% CI) 0.40 [0.27, 0.61]
9.1 > 90% 1 Hazard Ratio (Random, 95% CI) 0.27 [0.04, 1.74]
9.2 80% - 90% 3 Hazard Ratio (Random, 95% CI) 0.41 [0.22, 0.77]
9.3 unknown 1 Hazard Ratio (Random, 95% CI) 0.63 [0.11, 3.65]
10 Allocation concealment 5 Hazard Ratio (Random, 95% CI) 0.40 [0.27, 0.61]
10.1 Allocation concealment
unclear
3 Hazard Ratio (Random, 95% CI) 0.46 [0.23, 0.89]
10.2 Allocation concealment
adequate
2 Hazard Ratio (Random, 95% CI) 0.30 [0.10, 0.87]
11 ITT-analysis 5 Hazard Ratio (Random, 95% CI) 0.40 [0.27, 0.61]
11.1 ITT-analysis 2 Hazard Ratio (Random, 95% CI) 0.30 [0.10, 0.87]
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11.2 No ITT-analysis 3 Hazard Ratio (Random, 95% CI) 0.46 [0.23, 0.89]
Comparison 2. Progression-Free Survival
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All trials 4 1208 Hazard Ratio (Random, 95% CI) 0.41 [0.25, 0.66]
2 Type of chemotherapy 4 Hazard Ratio (Random, 95% CI) 0.41 [0.25, 0.66]
2.1 ABVD 2 Hazard Ratio (Random, 95% CI) 0.47 [0.16, 1.35]
2.2 CVPP 1 Hazard Ratio (Random, 95% CI) 0.55 [0.35, 0.86]
2.3 EBVP 1 Hazard Ratio (Random, 95% CI) 0.27 [0.17, 0.43]
3 Proportion of patients early
favourable
4 429 Hazard Ratio (Random, 95% CI) 0.41 [0.25, 0.66]
3.1 All patients early
favourable
1 0 Hazard Ratio (Random, 95% CI) 0.27 [0.17, 0.43]
3.2 mixed patient population
(~1/3 to 1/2)
2 429 Hazard Ratio (Random, 95% CI) 0.61 [0.41, 0.90]
3.3 All patients early
unfavourable
1 0 Hazard Ratio (Random, 95% CI) 0.29 [0.17, 0.48]
4 Definition of progression 4 Hazard Ratio (Random, 95% CI) 0.41 [0.25, 0.66]
4.1 In CR patients 1 Hazard Ratio (Random, 95% CI) 0.27 [0.17, 0.43]
4.2 Progress in all patients 2 Hazard Ratio (Random, 95% CI) 0.61 [0.41, 0.90]
4.3 Unclear 1 Hazard Ratio (Random, 95% CI) 0.29 [0.17, 0.48]
5 Timing of radiotherapy 4 Hazard Ratio (Random, 95% CI) 0.41 [0.25, 0.66]
5.1 Radiotherapy after
chemotherapy
2 Hazard Ratio (Random, 95% CI) 0.45 [0.15, 1.41]
5.2 Sandwich technique
(CT-RT-CT)
2 Hazard Ratio (Random, 95% CI) 0.40 [0.22, 0.75]
6 Type of radiotherapy 4 Hazard Ratio (Random, 95% CI) 0.41 [0.25, 0.66]
6.1 Involved field 2 Hazard Ratio (Random, 95% CI) 0.38 [0.19, 0.78]
6.2 Extended field 1 Hazard Ratio (Random, 95% CI) 0.29 [0.17, 0.48]
6.3 Mixed 1 Hazard Ratio (Random, 95% CI) 0.85 [0.37, 1.94]
7 Length of follow-up 4 Hazard Ratio (Random, 95% CI) 0.41 [0.25, 0.66]
7.1 Median follow-up ≤ 6
years
3 Hazard Ratio (Random, 95% CI) 0.47 [0.25, 0.89]
7.2 Median follow-up > 6
years
1 Hazard Ratio (Random, 95% CI) 0.29 [0.17, 0.48]
8 Allocation concealment 4 Hazard Ratio (Random, 95% CI) 0.41 [0.25, 0.66]
8.1 Allocation concealment
unclear
2 Hazard Ratio (Random, 95% CI) 0.40 [0.22, 0.75]
8.2 Allocation concealment
adequate
2 Hazard Ratio (Random, 95% CI) 0.45 [0.15, 1.41]
9 ITT-Analysis 4 Hazard Ratio (Random, 95% CI) 0.41 [0.25, 0.65]
9.1 ITT-analysis 2 Hazard Ratio (Random, 95% CI) 0.44 [0.15, 1.30]
9.2 No ITT-analysis 2 Hazard Ratio (Random, 95% CI) 0.40 [0.22, 0.75]
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Comparison 3. Complete Response Rate
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All trials 4 653 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.98, 1.17]
2 Type of Chemotherapy 4 653 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.98, 1.17]
2.1 CVPP 2 314 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.88, 1.74]
2.2 ABVD 2 339 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.95, 1.09]
3 ITT-analysis 4 653 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.98, 1.17]
3.1 ITT-analysis 1 138 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.92, 1.09]
3.2 no ITT-analysis 3 515 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.99, 1.24]
4 Number of evaluable patients 4 653 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.98, 1.17]
4.1 < 10% not evaluated 3 616 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.99, 1.11]
4.2 ≥ 10% not evaluated 1 37 Risk Ratio (M-H, Random, 95% CI) 1.55 [1.06, 2.27]
Comparison 4. Overall Response Rate
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All Trials 3 616 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.96, 1.04]
Analysis 1.1. Comparison 1 Overall Survival, Outcome 1 All trials.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 1 Overall Survival
Outcome: 1 All trials
Study or subgroup CMT CT-alone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
CALGB 7751 19 18 -0.47 (0.9) 5.4 % 0.63 [ 0.11, 3.65 ]
EORTC-GELA H9-F 448 130 -1.2925 (0.9426) 4.9 % 0.27 [ 0.04, 1.74 ]
GATLA 9-H-77 135 142 -0.3484 (0.3651) 31.0 % 0.71 [ 0.35, 1.44 ]
Mexico B2H031 102 99 -1.225 (0.2852) 48.9 % 0.29 [ 0.17, 0.51 ]
MSKCC trial #90-44 76 76 -1.1671 (0.6667) 9.7 % 0.31 [ 0.08, 1.15 ]
Total (95% CI) 100.0 % 0.40 [ 0.27, 0.61 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.14, df = 4 (P = 0.39); I2 =3%
Test for overall effect: Z = 4.33 (P = 0.000015)
0.05 0.2 1 5 20
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Analysis 1.2. Comparison 1 Overall Survival, Outcome 2 Excluding the trial with highest weight (Aviles).
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 1 Overall Survival
Outcome: 2 Excluding the trial with highest weight (Aviles)
Study or subgroup CMT CT-alone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
CALGB 7751 19 18 -0.31 (0.68) 16.6 % 0.73 [ 0.19, 2.78 ]
EORTC-GELA H9-F 448 130 -1.2925 (0.9426) 8.6 % 0.27 [ 0.04, 1.74 ]
GATLA 9-H-77 135 142 -0.3484 (0.3651) 57.5 % 0.71 [ 0.35, 1.44 ]
MSKCC trial #90-44 76 76 -1.1671 (0.6667) 17.3 % 0.31 [ 0.08, 1.15 ]
Total (95% CI) 100.0 % 0.57 [ 0.33, 0.98 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.90, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.041)
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Analysis 1.3. Comparison 1 Overall Survival, Outcome 3 Proportion of patients early favourable.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 1 Overall Survival
Outcome: 3 Proportion of patients early favourable
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 All patients early favourable
EORTC-GELA H9-F -1.2925 (0.9426) 4.9 % 0.27 [ 0.04, 1.74 ]
Subtotal (95% CI) 4.9 % 0.27 [ 0.04, 1.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
2 ˜ 1/3 to 1/2 patients early unfavourable
GATLA 9-H-77 -0.3484 (0.3651) 31.0 % 0.71 [ 0.35, 1.44 ]
MSKCC trial #90-44 -1.1671 (0.6667) 9.7 % 0.31 [ 0.08, 1.15 ]
Subtotal (95% CI) 40.8 % 0.57 [ 0.28, 1.15 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 1.57 (P = 0.12)
3 All patients early unfavourable
CALGB 7751 -0.47 (0.9) 5.4 % 0.63 [ 0.11, 3.65 ]
Mexico B2H031 -1.225 (0.2852) 48.9 % 0.29 [ 0.17, 0.51 ]
Subtotal (95% CI) 54.3 % 0.31 [ 0.18, 0.54 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.64, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 4.25 (P = 0.000021)
Total (95% CI) 100.0 % 0.40 [ 0.27, 0.61 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.14, df = 4 (P = 0.39); I2 =3%
Test for overall effect: Z = 4.33 (P = 0.000015)
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Analysis 1.4. Comparison 1 Overall Survival, Outcome 4 Bulky vs non-bulky.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 1 Overall Survival
Outcome: 4 Bulky vs non-bulky
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Bulky disease
Mexico B2H031 -1.225 (0.2852) 78.5 % 0.29 [ 0.17, 0.51 ]
Subtotal (95% CI) 78.5 % 0.29 [ 0.17, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.30 (P = 0.000017)
2 Non-bulky disease
EORTC-GELA H9-F -1.2925 (0.9426) 7.2 % 0.27 [ 0.04, 1.74 ]
MSKCC trial #90-44 -1.1671 (0.6667) 14.4 % 0.31 [ 0.08, 1.15 ]
Subtotal (95% CI) 21.5 % 0.30 [ 0.10, 0.87 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.026)
Total (95% CI) 100.0 % 0.29 [ 0.18, 0.48 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 4.84 (P < 0.00001)
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Analysis 1.5. Comparison 1 Overall Survival, Outcome 5 Timing of radiotherapy.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 1 Overall Survival
Outcome: 5 Timing of radiotherapy
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Radiotherapy after chemotherapy
EORTC-GELA H9-F -1.2925 (0.9426) 4.9 % 0.27 [ 0.04, 1.74 ]
MSKCC trial #90-44 -1.1671 (0.6667) 9.7 % 0.31 [ 0.08, 1.15 ]
Subtotal (95% CI) 14.6 % 0.30 [ 0.10, 0.87 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.026)
2 Sandwich technique (CT-RT-CT)
GATLA 9-H-77 -0.3484 (0.3651) 31.0 % 0.71 [ 0.35, 1.44 ]
Mexico B2H031 -1.225 (0.2852) 48.9 % 0.29 [ 0.17, 0.51 ]
Subtotal (95% CI) 80.0 % 0.44 [ 0.19, 1.04 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 3.58, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 1.87 (P = 0.062)
3 Chemotherapy after radiotherapy
CALGB 7751 -0.47 (0.9) 5.4 % 0.63 [ 0.11, 3.65 ]
Subtotal (95% CI) 5.4 % 0.63 [ 0.11, 3.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Total (95% CI) 100.0 % 0.40 [ 0.27, 0.61 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.14, df = 4 (P = 0.39); I2 =3%
Test for overall effect: Z = 4.33 (P = 0.000015)
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Analysis 1.6. Comparison 1 Overall Survival, Outcome 6 Type of radiotherapy.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 1 Overall Survival
Outcome: 6 Type of radiotherapy
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Involved field
CALGB 7751 -0.47 (0.9) 5.4 % 0.63 [ 0.11, 3.65 ]
EORTC-GELA H9-F -1.2925 (0.9426) 4.9 % 0.27 [ 0.04, 1.74 ]
GATLA 9-H-77 -0.3484 (0.3651) 31.0 % 0.71 [ 0.35, 1.44 ]
Subtotal (95% CI) 41.3 % 0.62 [ 0.33, 1.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
2 Extended field
Mexico B2H031 -1.225 (0.2852) 48.9 % 0.29 [ 0.17, 0.51 ]
Subtotal (95% CI) 48.9 % 0.29 [ 0.17, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.30 (P = 0.000017)
3 Mixed
MSKCC trial #90-44 -1.1671 (0.6667) 9.7 % 0.31 [ 0.08, 1.15 ]
Subtotal (95% CI) 9.7 % 0.31 [ 0.08, 1.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.080)
Total (95% CI) 100.0 % 0.40 [ 0.27, 0.61 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.14, df = 4 (P = 0.39); I2 =3%
Test for overall effect: Z = 4.33 (P = 0.000015)
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Analysis 1.7. Comparison 1 Overall Survival, Outcome 7 Type of chemotherapy.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 1 Overall Survival
Outcome: 7 Type of chemotherapy
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 ABVD
Mexico B2H031 -1.2245 (0.2852) 50.4 % 0.29 [ 0.17, 0.51 ]
MSKCC trial #90-44 -1.1733 (0.6667) 9.2 % 0.31 [ 0.08, 1.14 ]
Subtotal (95% CI) 59.6 % 0.30 [ 0.18, 0.50 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 4.64 (P < 0.00001)
2 CVPP
CALGB 7751 -0.47 (0.9) 5.1 % 0.63 [ 0.11, 3.65 ]
GATLA 9-H-77 -0.3786 (0.3651) 30.7 % 0.68 [ 0.33, 1.40 ]
Subtotal (95% CI) 35.8 % 0.68 [ 0.35, 1.31 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
3 EBVP
EORTC-GELA H9-F -1.2931 (0.9407) 4.6 % 0.27 [ 0.04, 1.73 ]
Subtotal (95% CI) 4.6 % 0.27 [ 0.04, 1.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Total (95% CI) 100.0 % 0.40 [ 0.27, 0.59 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.89, df = 4 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 4.57 (P < 0.00001)
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Analysis 1.8. Comparison 1 Overall Survival, Outcome 8 Length of follow-up.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 1 Overall Survival
Outcome: 8 Length of follow-up
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Six years or less
CALGB 7751 -0.47 (0.9) 5.4 % 0.63 [ 0.11, 3.65 ]
EORTC-GELA H9-F -1.2925 (0.9426) 4.9 % 0.27 [ 0.04, 1.74 ]
GATLA 9-H-77 -0.3484 (0.3651) 31.0 % 0.71 [ 0.35, 1.44 ]
MSKCC trial #90-44 -1.1671 (0.6667) 9.7 % 0.31 [ 0.08, 1.15 ]
Subtotal (95% CI) 51.1 % 0.55 [ 0.31, 0.96 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.76, df = 3 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.037)
2 More than six years
Mexico B2H031 -1.225 (0.2852) 48.9 % 0.29 [ 0.17, 0.51 ]
Subtotal (95% CI) 48.9 % 0.29 [ 0.17, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.30 (P = 0.000017)
Total (95% CI) 100.0 % 0.40 [ 0.27, 0.61 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.14, df = 4 (P = 0.39); I2 =3%
Test for overall effect: Z = 4.33 (P = 0.000015)
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Analysis 1.9. Comparison 1 Overall Survival, Outcome 9 4 year survival in the CT group.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 1 Overall Survival
Outcome: 9 4 year survival in the CT group
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 > 90%
EORTC-GELA H9-F -1.2925 (0.9426) 4.9 % 0.27 [ 0.04, 1.74 ]
Subtotal (95% CI) 4.9 % 0.27 [ 0.04, 1.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
2 80% - 90%
GATLA 9-H-77 -0.3484 (0.3651) 31.0 % 0.71 [ 0.35, 1.44 ]
Mexico B2H031 -1.225 (0.2852) 48.9 % 0.29 [ 0.17, 0.51 ]
MSKCC trial #90-44 -1.1671 (0.6667) 9.7 % 0.31 [ 0.08, 1.15 ]
Subtotal (95% CI) 89.7 % 0.41 [ 0.22, 0.77 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 3.73, df = 2 (P = 0.15); I2 =46%
Test for overall effect: Z = 2.80 (P = 0.0051)
3 unknown
CALGB 7751 -0.47 (0.9) 5.4 % 0.63 [ 0.11, 3.65 ]
Subtotal (95% CI) 5.4 % 0.63 [ 0.11, 3.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Total (95% CI) 100.0 % 0.40 [ 0.27, 0.61 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.14, df = 4 (P = 0.39); I2 =3%
Test for overall effect: Z = 4.33 (P = 0.000015)
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Analysis 1.10. Comparison 1 Overall Survival, Outcome 10 Allocation concealment.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 1 Overall Survival
Outcome: 10 Allocation concealment
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Allocation concealment unclear
CALGB 7751 -0.47 (0.9) 5.4 % 0.63 [ 0.11, 3.65 ]
GATLA 9-H-77 -0.3484 (0.3651) 31.0 % 0.71 [ 0.35, 1.44 ]
Mexico B2H031 -1.225 (0.2852) 48.9 % 0.29 [ 0.17, 0.51 ]
Subtotal (95% CI) 85.4 % 0.46 [ 0.23, 0.89 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 3.79, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 2.30 (P = 0.022)
2 Allocation concealment adequate
EORTC-GELA H9-F -1.2925 (0.9426) 4.9 % 0.27 [ 0.04, 1.74 ]
MSKCC trial #90-44 -1.1671 (0.6667) 9.7 % 0.31 [ 0.08, 1.15 ]
Subtotal (95% CI) 14.6 % 0.30 [ 0.10, 0.87 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.026)
Total (95% CI) 100.0 % 0.40 [ 0.27, 0.61 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.14, df = 4 (P = 0.39); I2 =3%
Test for overall effect: Z = 4.33 (P = 0.000015)
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Analysis 1.11. Comparison 1 Overall Survival, Outcome 11 ITT-analysis.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 1 Overall Survival
Outcome: 11 ITT-analysis
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 ITT-analysis
EORTC-GELA H9-F -1.2925 (0.9426) 4.9 % 0.27 [ 0.04, 1.74 ]
MSKCC trial #90-44 -1.1671 (0.6667) 9.7 % 0.31 [ 0.08, 1.15 ]
Subtotal (95% CI) 14.6 % 0.30 [ 0.10, 0.87 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.026)
2 No ITT-analysis
CALGB 7751 -0.47 (0.9) 5.4 % 0.63 [ 0.11, 3.65 ]
GATLA 9-H-77 -0.3484 (0.3651) 31.0 % 0.71 [ 0.35, 1.44 ]
Mexico B2H031 -1.225 (0.2852) 48.9 % 0.29 [ 0.17, 0.51 ]
Subtotal (95% CI) 85.4 % 0.46 [ 0.23, 0.89 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 3.79, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 2.30 (P = 0.022)
Total (95% CI) 100.0 % 0.40 [ 0.27, 0.61 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.14, df = 4 (P = 0.39); I2 =3%
Test for overall effect: Z = 4.33 (P = 0.000015)
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Analysis 2.1. Comparison 2 Progression-Free Survival, Outcome 1 All trials.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 2 Progression-Free Survival
Outcome: 1 All trials
Study or subgroup CMT CT-alone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
EORTC-GELA H9-F 448 130 -1.32 (0.24) 27.6 % 0.27 [ 0.17, 0.43 ]
GATLA 9-H-77 135 142 -0.6 (0.23) 28.2 % 0.55 [ 0.35, 0.86 ]
Mexico B2H031 102 99 -1.24 (0.26) 26.4 % 0.29 [ 0.17, 0.48 ]
MSKCC trial #90-44 76 76 -0.16 (0.42) 17.8 % 0.85 [ 0.37, 1.94 ]
Total (95% CI) 100.0 % 0.41 [ 0.25, 0.66 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 9.47, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 3.64 (P = 0.00028)
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Analysis 2.2. Comparison 2 Progression-Free Survival, Outcome 2 Type of chemotherapy.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 2 Progression-Free Survival
Outcome: 2 Type of chemotherapy
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 ABVD
Mexico B2H031 -1.24 (0.26) 26.4 % 0.29 [ 0.17, 0.48 ]
MSKCC trial #90-44 -0.16 (0.42) 17.8 % 0.85 [ 0.37, 1.94 ]
Subtotal (95% CI) 44.2 % 0.47 [ 0.16, 1.35 ]
Heterogeneity: Tau2 = 0.46; Chi2 = 4.78, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 1.40 (P = 0.16)
2 CVPP
GATLA 9-H-77 -0.6 (0.23) 28.2 % 0.55 [ 0.35, 0.86 ]
Subtotal (95% CI) 28.2 % 0.55 [ 0.35, 0.86 ]
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(. . . Continued)
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 2.61 (P = 0.0091)
3 EBVP
EORTC-GELA H9-F -1.32 (0.24) 27.6 % 0.27 [ 0.17, 0.43 ]
Subtotal (95% CI) 27.6 % 0.27 [ 0.17, 0.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.50 (P < 0.00001)
Total (95% CI) 100.0 % 0.41 [ 0.25, 0.66 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 9.47, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 3.64 (P = 0.00028)
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Analysis 2.3. Comparison 2 Progression-Free Survival, Outcome 3 Proportion of patients early favourable.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 2 Progression-Free Survival
Outcome: 3 Proportion of patients early favourable
Study or subgroup CMT CT-alone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 All patients early favourable
EORTC-GELA H9-F 0 0 -1.32 (0.24) 27.6 % 0.27 [ 0.17, 0.43 ]
Subtotal (95% CI) 27.6 % 0.27 [ 0.17, 0.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.50 (P < 0.00001)
2 mixed patient population (˜1/3 to 1/2)
GATLA 9-H-77 135 142 -0.6 (0.23) 28.2 % 0.55 [ 0.35, 0.86 ]
MSKCC trial #90-44 76 76 -0.16 (0.42) 17.8 % 0.85 [ 0.37, 1.94 ]
Subtotal (95% CI) 46.0 % 0.61 [ 0.41, 0.90 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 2.47 (P = 0.013)
3 All patients early unfavourable
Mexico B2H031 0 0 -1.24 (0.26) 26.4 % 0.29 [ 0.17, 0.48 ]
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(. . . Continued)
Study or subgroup CMT CT-alone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 26.4 % 0.29 [ 0.17, 0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.77 (P < 0.00001)
Total (95% CI) 100.0 % 0.41 [ 0.25, 0.66 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 9.47, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 3.64 (P = 0.00028)
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Analysis 2.4. Comparison 2 Progression-Free Survival, Outcome 4 Definition of progression.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 2 Progression-Free Survival
Outcome: 4 Definition of progression
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 In CR patients
EORTC-GELA H9-F -1.32 (0.24) 27.6 % 0.27 [ 0.17, 0.43 ]
Subtotal (95% CI) 27.6 % 0.27 [ 0.17, 0.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.50 (P < 0.00001)
2 Progress in all patients
GATLA 9-H-77 -0.6 (0.23) 28.2 % 0.55 [ 0.35, 0.86 ]
MSKCC trial #90-44 -0.16 (0.42) 17.8 % 0.85 [ 0.37, 1.94 ]
Subtotal (95% CI) 46.0 % 0.61 [ 0.41, 0.90 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 2.47 (P = 0.013)
3 Unclear
Mexico B2H031 -1.24 (0.26) 26.4 % 0.29 [ 0.17, 0.48 ]
Subtotal (95% CI) 26.4 % 0.29 [ 0.17, 0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.77 (P < 0.00001)
Total (95% CI) 100.0 % 0.41 [ 0.25, 0.66 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 9.47, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 3.64 (P = 0.00028)
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Analysis 2.5. Comparison 2 Progression-Free Survival, Outcome 5 Timing of radiotherapy.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 2 Progression-Free Survival
Outcome: 5 Timing of radiotherapy
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Radiotherapy after chemotherapy
EORTC-GELA H9-F -1.32 (0.24) 27.6 % 0.27 [ 0.17, 0.43 ]
MSKCC trial #90-44 -0.16 (0.42) 17.8 % 0.85 [ 0.37, 1.94 ]
Subtotal (95% CI) 45.4 % 0.45 [ 0.15, 1.41 ]
Heterogeneity: Tau2 = 0.56; Chi2 = 5.75, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 1.37 (P = 0.17)
2 Sandwich technique (CT-RT-CT)
GATLA 9-H-77 -0.6 (0.23) 28.2 % 0.55 [ 0.35, 0.86 ]
Mexico B2H031 -1.24 (0.26) 26.4 % 0.29 [ 0.17, 0.48 ]
Subtotal (95% CI) 54.6 % 0.40 [ 0.22, 0.75 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 3.40, df = 1 (P = 0.07); I2 =71%
Test for overall effect: Z = 2.84 (P = 0.0045)
Total (95% CI) 100.0 % 0.41 [ 0.25, 0.66 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 9.47, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 3.64 (P = 0.00028)
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Analysis 2.6. Comparison 2 Progression-Free Survival, Outcome 6 Type of radiotherapy.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 2 Progression-Free Survival
Outcome: 6 Type of radiotherapy
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Involved field
EORTC-GELA H9-F -1.32 (0.24) 27.6 % 0.27 [ 0.17, 0.43 ]
GATLA 9-H-77 -0.6 (0.23) 28.2 % 0.55 [ 0.35, 0.86 ]
Subtotal (95% CI) 55.8 % 0.38 [ 0.19, 0.78 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 4.69, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 2.66 (P = 0.0079)
2 Extended field
Mexico B2H031 -1.24 (0.26) 26.4 % 0.29 [ 0.17, 0.48 ]
Subtotal (95% CI) 26.4 % 0.29 [ 0.17, 0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.77 (P < 0.00001)
3 Mixed
MSKCC trial #90-44 -0.16 (0.42) 17.8 % 0.85 [ 0.37, 1.94 ]
Subtotal (95% CI) 17.8 % 0.85 [ 0.37, 1.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
Total (95% CI) 100.0 % 0.41 [ 0.25, 0.66 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 9.47, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 3.64 (P = 0.00028)
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Analysis 2.7. Comparison 2 Progression-Free Survival, Outcome 7 Length of follow-up.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 2 Progression-Free Survival
Outcome: 7 Length of follow-up
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Median follow-up≤ 6 years
EORTC-GELA H9-F -1.32 (0.24) 27.6 % 0.27 [ 0.17, 0.43 ]
GATLA 9-H-77 -0.6 (0.23) 28.2 % 0.55 [ 0.35, 0.86 ]
MSKCC trial #90-44 -0.16 (0.42) 17.8 % 0.85 [ 0.37, 1.94 ]
Subtotal (95% CI) 73.6 % 0.47 [ 0.25, 0.89 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 7.71, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 2.33 (P = 0.020)
2 Median follow-up > 6 years
Mexico B2H031 -1.24 (0.26) 26.4 % 0.29 [ 0.17, 0.48 ]
Subtotal (95% CI) 26.4 % 0.29 [ 0.17, 0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.77 (P < 0.00001)
Total (95% CI) 100.0 % 0.41 [ 0.25, 0.66 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 9.47, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 3.64 (P = 0.00028)
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Analysis 2.8. Comparison 2 Progression-Free Survival, Outcome 8 Allocation concealment.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 2 Progression-Free Survival
Outcome: 8 Allocation concealment
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Allocation concealment unclear
GATLA 9-H-77 -0.6 (0.23) 28.2 % 0.55 [ 0.35, 0.86 ]
Mexico B2H031 -1.24 (0.26) 26.4 % 0.29 [ 0.17, 0.48 ]
Subtotal (95% CI) 54.6 % 0.40 [ 0.22, 0.75 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 3.40, df = 1 (P = 0.07); I2 =71%
Test for overall effect: Z = 2.84 (P = 0.0045)
2 Allocation concealment adequate
EORTC-GELA H9-F -1.32 (0.24) 27.6 % 0.27 [ 0.17, 0.43 ]
MSKCC trial #90-44 -0.16 (0.42) 17.8 % 0.85 [ 0.37, 1.94 ]
Subtotal (95% CI) 45.4 % 0.45 [ 0.15, 1.41 ]
Heterogeneity: Tau2 = 0.56; Chi2 = 5.75, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 1.37 (P = 0.17)
Total (95% CI) 100.0 % 0.41 [ 0.25, 0.66 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 9.47, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 3.64 (P = 0.00028)
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Analysis 2.9. Comparison 2 Progression-Free Survival, Outcome 9 ITT-Analysis.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 2 Progression-Free Survival
Outcome: 9 ITT-Analysis
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 ITT-analysis
EORTC-GELA H9-F -1.32 (0.24) 27.7 % 0.27 [ 0.17, 0.43 ]
MSKCC trial #90-44 -0.21 (0.42) 17.6 % 0.81 [ 0.36, 1.85 ]
Subtotal (95% CI) 45.3 % 0.44 [ 0.15, 1.30 ]
Heterogeneity: Tau2 = 0.50; Chi2 = 5.27, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 1.48 (P = 0.14)
2 No ITT-analysis
GATLA 9-H-77 -0.6 (0.23) 28.3 % 0.55 [ 0.35, 0.86 ]
Mexico B2H031 -1.24 (0.26) 26.4 % 0.29 [ 0.17, 0.48 ]
Subtotal (95% CI) 54.7 % 0.40 [ 0.22, 0.75 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 3.40, df = 1 (P = 0.07); I2 =71%
Test for overall effect: Z = 2.84 (P = 0.0045)
Total (95% CI) 100.0 % 0.41 [ 0.25, 0.65 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 9.04, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 3.77 (P = 0.00017)
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Analysis 3.1. Comparison 3 Complete Response Rate, Outcome 1 All trials.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 3 Complete Response Rate
Outcome: 1 All trials
Study or subgroup CMT CT-alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
CALGB 7751 18/19 11/18 5.0 % 1.55 [ 1.06, 2.27 ]
GATLA 9-H-77 126/135 121/142 34.9 % 1.10 [ 1.01, 1.19 ]
Mexico B2H031 87/102 80/99 25.3 % 1.06 [ 0.93, 1.20 ]
MSKCC trial #90-44 65/69 65/69 34.7 % 1.00 [ 0.92, 1.09 ]
Total (95% CI) 325 328 100.0 % 1.07 [ 0.98, 1.17 ]
Total events: 296 (CMT), 277 (CT-alone)
Heterogeneity: Tau2 = 0.00; Chi2 = 6.96, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 1.46 (P = 0.14)
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Analysis 3.2. Comparison 3 Complete Response Rate, Outcome 2 Type of Chemotherapy.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 3 Complete Response Rate
Outcome: 2 Type of Chemotherapy
Study or subgroup CMT CT-alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 CVPP
CALGB 7751 18/19 11/18 5.0 % 1.55 [ 1.06, 2.27 ]
GATLA 9-H-77 126/135 121/142 34.9 % 1.10 [ 1.01, 1.19 ]
Subtotal (95% CI) 154 160 40.0 % 1.24 [ 0.88, 1.74 ]
Total events: 144 (CMT), 132 (CT-alone)
Heterogeneity: Tau2 = 0.05; Chi2 = 3.26, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 1.25 (P = 0.21)
2 ABVD
Mexico B2H031 87/102 80/99 25.3 % 1.06 [ 0.93, 1.20 ]
MSKCC trial #90-44 65/69 65/69 34.7 % 1.00 [ 0.92, 1.09 ]
Subtotal (95% CI) 171 168 60.0 % 1.02 [ 0.95, 1.09 ]
Total events: 152 (CMT), 145 (CT-alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Total (95% CI) 325 328 100.0 % 1.07 [ 0.98, 1.17 ]
Total events: 296 (CMT), 277 (CT-alone)
Heterogeneity: Tau2 = 0.00; Chi2 = 6.96, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 1.46 (P = 0.14)
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Analysis 3.3. Comparison 3 Complete Response Rate, Outcome 3 ITT-analysis.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 3 Complete Response Rate
Outcome: 3 ITT-analysis
Study or subgroup CMT CT-alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 ITT-analysis
MSKCC trial #90-44 65/69 65/69 34.7 % 1.00 [ 0.92, 1.09 ]
Subtotal (95% CI) 69 69 34.7 % 1.00 [ 0.92, 1.09 ]
Total events: 65 (CMT), 65 (CT-alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 no ITT-analysis
CALGB 7751 18/19 11/18 5.0 % 1.55 [ 1.06, 2.27 ]
GATLA 9-H-77 126/135 121/142 34.9 % 1.10 [ 1.01, 1.19 ]
Mexico B2H031 87/102 80/99 25.3 % 1.06 [ 0.93, 1.20 ]
Subtotal (95% CI) 256 259 65.3 % 1.11 [ 0.99, 1.24 ]
Total events: 231 (CMT), 212 (CT-alone)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.54, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 1.83 (P = 0.067)
Total (95% CI) 325 328 100.0 % 1.07 [ 0.98, 1.17 ]
Total events: 296 (CMT), 277 (CT-alone)
Heterogeneity: Tau2 = 0.00; Chi2 = 6.96, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 1.46 (P = 0.14)
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Analysis 3.4. Comparison 3 Complete Response Rate, Outcome 4 Number of evaluable patients.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 3 Complete Response Rate
Outcome: 4 Number of evaluable patients
Study or subgroup CMT CT-alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 < 10% not evaluated
GATLA 9-H-77 126/135 121/142 34.9 % 1.10 [ 1.01, 1.19 ]
Mexico B2H031 87/102 80/99 25.3 % 1.06 [ 0.93, 1.20 ]
MSKCC trial #90-44 65/69 65/69 34.7 % 1.00 [ 0.92, 1.09 ]
Subtotal (95% CI) 306 310 95.0 % 1.05 [ 0.99, 1.11 ]
Total events: 278 (CMT), 266 (CT-alone)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.51, df = 2 (P = 0.28); I2 =20%
Test for overall effect: Z = 1.55 (P = 0.12)
2≥ 10% not evaluated
CALGB 7751 18/19 11/18 5.0 % 1.55 [ 1.06, 2.27 ]
Subtotal (95% CI) 19 18 5.0 % 1.55 [ 1.06, 2.27 ]
Total events: 18 (CMT), 11 (CT-alone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
Total (95% CI) 325 328 100.0 % 1.07 [ 0.98, 1.17 ]
Total events: 296 (CMT), 277 (CT-alone)
Heterogeneity: Tau2 = 0.00; Chi2 = 6.96, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 1.46 (P = 0.14)
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Analysis 4.1. Comparison 4 Overall Response Rate, Outcome 1 All Trials.
Review: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Comparison: 4 Overall Response Rate
Outcome: 1 All Trials
Study or subgroup CMT CT-alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
GATLA 9-H-77 128/135 135/142 59.1 % 1.00 [ 0.94, 1.05 ]
Mexico B2H031 87/102 81/99 11.6 % 1.04 [ 0.92, 1.18 ]
MSKCC trial #90-44 65/69 66/69 29.3 % 0.98 [ 0.91, 1.06 ]
Total (95% CI) 306 310 100.0 % 1.00 [ 0.96, 1.04 ]
Total events: 280 (CMT), 282 (CT-alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.77, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
The following search strategy was used to search CENTRAL:
1. (favourable or unfavourable)
2. ((earl* or low* or limit*) near/3 (stag* or grad*))
3. (intermediate*)
4. (bulky)
5. (#1 OR #2 OR #3 OR #4)
6. MeSH descriptor LYMPHOMA, this term only
7. MeSH descriptor HODGKIN DISEASE explode all trees
8. (hodgkin* near/2 (disease* or granulom*))
9. (reticulolymphosarcom* or germinoblastom*)
10. (malignan* near/2 (lymphogranulom* or granulom*))
11. (#6 OR #7 OR #8 OR #9 OR #10)
12. MeSH descriptor ANTINEOPLASTIC AGENTS explode all trees
13. MeSH descriptor REMISSION INDUCTION explode all trees
14. MeSH descriptor ANTINEOPLASTIC PROTOCOLS explode all trees
15. ((consolidat* or induct* or maintenance or conditioning*) and (therap* or treat* or regimen* or patient*))
16. ((therap* or induc*) near/3 remission*)
17. (chemotherap* or chemo-therap*)
18. (Antineoplast* or anti-neoplast*)
19. ((cytosta* or cytotox*) near/2 (therap* or treat* or regimen*))
20. MeSH descriptor RADIOTHERAPY explode all trees
21. (radiotherap* or radio-therap*)
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22. (chemoradiotherap* or chemo-radio-therap*)
23. MeSH descriptor COMBINED MODALITY THERAPY explode all trees
24. ((multimodal* or multi-modal*) near/3 (treat* or therap*))
25. MeSH descriptor LYMPHATIC IRRADIATION explode all trees
26. (combi* near/3 modalit*)
27. (#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26)
28. (#5 AND #11 AND #27)
The search strategy was modified the following updated search strategy was also used and will be used for further updates:
#1 (favourable or favorable or unfavourable or unfavorable)
#2 (I-II or I-III)
#3 (earl* near/3 grad*) or (earl* near/3 stag*) or (low* near/3 stag*) or (low* near/3 grad*)
#4 (limit* near/3 stag*) or (limit* near/3 grad*)
#5 (intermediate*)
#6 (bulky)
#7 (#1 OR #2 OR #3 OR #4 OR #5 OR #6)
#8 MeSH descriptor Lymphoma explode all trees
#9 MeSH descriptor Hodgkin Disease explode all trees
#10 (Germinoblastom* or Reticulolymphosarcom*)
#11 (hodgkin*)
#12 (malignan* near/2 lymphogranulom*) or (malignan* near/2 granulom*)
#13 (#8 OR #9 OR #10 OR #11 OR #12)
#14 MeSH descriptor Antineoplastic Agents explode all trees
#15 MeSH descriptor Remission Induction explode all trees
#16 MeSH descriptor Antineoplastic Protocols explode all trees
#17 (consolidat* and therap*) or (consolidat* and treat*) or (consolidat* and regimen*) or (consolidat* and patient*)
#18 (induct* and therap*) or (induct* and treat*) or (induct* and regimen*) or (induct* and patient*)
#19 (maintenance* and therap*) or (maintenance* and treat* ) or (maintenance* and regimen*) or (maintenance* and patient*)
#20 (conditioning* and therap*) or (conditioning* and treat*) or (conditioning* and regimen*) or (conditioning* and patient*)
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(Continued)
#21 (therap* near/3 remission*) or (induc* near/3 remission*)
#22 (chemotherap* or chemo-therap*)
#23 (Antineoplast* or Anti-neoplast*)
#24 (cytosta* near/2 therap* ) or (cytosta* near/2 treat*) or (cytosta* near/2 regimen*)
#25 (cytotox* near/2 therap*) or (cytotox* near/2 treat*) or (cytotox* near/2 regimen*)
#26 (#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25)
#27 MeSH descriptor Radiotherapy explode all trees
#28 (radiotherap* or radio-therap*)
#29 MeSH descriptor Lymphatic Irradiation explode all trees
#30 (#27 OR #28 OR #29)
#31 (#26 AND #30)
#32 (chemoradiotherap*) or (chemo-radiotherap*)
#33 MeSH descriptor Combined Modality Therapy explode all trees
#34 (multimodal* near/3 therap*) or (multimodal* near/3 treat*) or (multi-modal* near/3 therap*) or (multi-modal* near/3 treat*)
#35 (combi* near/3 modalit*)
#36 (#32 OR #33 OR #34 OR #35)
#37 (#31 OR #36)
#38 (#13 AND #37)
#39 (#7 AND #13 AND #37)
#40 (#39), from 2008 to 2009
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Appendix 2. MEDLINE search strategy
The following search strategy was used to search MEDLINE:
1. (favourable or unfavourable).tw,kf,ot.
2. ((earl$ or low$ or limit$) adj3 (stag$ or grad$)).tw,kf,ot.
3. intermediate$.tw,kf,ot.
4. bulky.tw,kf,ot.
5. or/1-4
6. *LYMPHOMA/
7. exp HODGKIN DISEASE/
8. Germinoblastom$.tw,kf,ot.
9. Reticulolymphosarcom$.tw,kf,ot.
10. Hodgkin$.tw,kf,ot.
11. (malignan$ adj2 (lymphogranulom$ or granulom$)).tw,kf,ot.
12. or/6-11
13. exp ANTINEOPLASTIC AGENTS/
14. REMISSION INDUCTION/
15. exp ANTINEOPLASTIC PROTOCOLS/
16. ((consolidat$ or induct$ or maintenance or conditioning$) and (therap$ or treat$ or regimen$ or patient$)).tw,kf,ot.
17. ((therap$ or induc$) adj3 remission$).tw,kf,ot.
18. (chemotherap$ or chemo-therap$).tw,kf,ot.
19. (Antineoplast$ or anti-neoplast$).tw,kf,ot.
20. ((cytosta$ or cytotox$) adj2 (therap$ or treat$ or regimen$)).tw,kf,ot.
21. exp RADIOTHERAPY/
22. (radiotherap$ or radio-therap$).tw,kf,ot.
23. (chemoradiotherap$ or chemo-radio-therap$).tw,kf,ot.
24. exp COMBINED MODALITY THERAPY/
25. ((multimodal$ or multi-modal$) adj3 (treat$ or therap$)).tw,kf,ot.
26. exp LYMPHATIC IRRADIATION/
27. (combi$ adj3 modalit$).tw,kf,ot.
28. or/13-27
29. randomized controlled trial.pt.
30. controlled clinical trial.pt.
31. RANDOMIZED CONTROLLED TRIALS/
32. RANDOM ALLOCATION/
33. DOUBLE BLIND METHOD/
34. SINGLE BLIND METHOD/
35. or/29-34
36. (ANIMALS not HUMANS).sh.
37. 35 not 36
38. clinical trial.pt.
39. exp CLINICAL TRIALS/
40. (clin$ adj25 trial$).ti,ab.
41. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
42. PLACEBOS/
43. placebo$.ti,ab.
44. random$.ti,ab.
45. RESEARCH DESIGN/
46. or/38-45
47. 46 not 36
48. 47 not 37
49. COMPARATIVE STUDY/
50. exp EVALUATION STUDIES/
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51. FOLLOW UP STUDIES/
52. PROSPECTIVE STUDIES/
53. (control$ or prospectiv$ or volunteer$).ti,ab.
54. or/49-53
55. 54 not 36
56. 55 not (37 or 48)
57. 37 or 48 or 56
58. 5 and 12 and 28 and 57
The search strategy was updated during the review process and the following search strategy was used in addition the the above one.
For updates the following search strategy will be used:
1 (favo?rable or unfavo?rable).tw,kf,ot.
2 (I-II or I-III).tw,kf,ot.
3 ((earl$ or low$ or limit$) adj3 (stag$ or grad$)).tw,kf,ot.
4 intermediate$.tw,kf,ot.
5 bulky.tw,kf,ot.
6 or/1-4
7 *Lymphoma/
8 exp Hodgkin Disease/
9 Germinoblastom$.tw,kf,ot.
10 Reticulolymphosarcom$.tw,kf,ot.
11 Hodgkin$.tw,kf,ot.
12 (malignan$ adj2 (lymphogranulom$ or granulom$)).tw,kf,ot.
13 or/7-12
14 exp Antineoplastic Agents/
15 Remission Induction/
16 exp antineoplastic protocols/
17 ((consolidat$ or induct$ or maintenance or conditioning$) and (therap$ or treat$ or regimen$ or patient$)).tw,kf,ot.
18 ((therap$ or induc$) adj3 remission$).tw,kf,ot.
19 (chemotherap$ or chemo-therap$).tw,kf,ot.
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(Continued)
20 (Antineoplast$ or anti-neoplast$).tw,kf,ot.
21 ((cytosta$ or cytotox$) adj2 (therap$ or treat$ or regimen$)).tw,kf,ot.
22 or/14-21
23 exp Radiotherapy/
24 (radiotherap$ or radio-therap$).tw,kf,ot.
25 exp Lymphatic Irradiation/
26 or/23-25
27 22 and 26
28 (chemoradiotherap$ or chemo-radio-therap$).tw,kf,ot.
29 exp Combined Modality Therapy/
30 ((multimodal$ or multi-modal$) adj3 (treat$ or therap$)).tw,kf,ot.
31 (combi$ adj3 modalit$).tw,kf,ot.
32 or/28-31
33 27 or 32
34 13 and 33
35 13 and 33 and 6
36 randomized controlled trial.pt.
37 controlled clinical trial.pt.
38 randomized controlled trials/
39 random allocation/
40 double blind method/
41 single blind method/
42 or/36-41
43 (ANIMALS not HUMANS).sh.
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(Continued)
44 42 not 43
45 clinical trial.pt.
46 exp clinical trial/
47 (clin$ adj25 trial$).ti,ab.
48 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
49 placebos/
50 placebo$.ti,ab.
51 random$.ti,ab.
52 research design/
53 or/45-52
54 53 not 43
55 54 not 44
56 comparative study/
57 exp evaluation studies/
58 follow up studies/
59 prospective studies/
60 (control$ or prospectiv$ or volunteer$).ti,ab.
61 or/56-60
62 61 not 43
63 62 not (44 or 55)
64 44 or 55 or 63
65 13 and 32 and 64
66 65 and 6
67 limit 66 to ed=20080401-20090204
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(Continued)
68 randomized controlled trial.pt.
69 controlled clinical trial.pt.
70 randomized controlled trials as topic/
71 random allocation/
72 double blind method/
73 single blind method/
74 or/68-73
75 (ANIMALS not HUMANS).sh.
76 74 not 75
77 clinical trial.pt.
78 exp clinical trial as topic/
79 (clin$ adj25 trial$).ti,ab.
80 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
81 placebos/
82 placebo$.ti,ab.
83 random$.ti,ab.
84 research design/
85 or/77-84
86 85 not 75
87 86 not 76
88 comparative study/
89 exp evaluation studies/
90 follow up studies/
91 prospective studies/
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(Continued)
92 (control$ or prospectiv$ or volunteer$).ti,ab.
93 or/88-92
94 93 not 75
95 94 not (76 or 87)
96 76 or 87 or 95
97 35 and 96
98 from 67 keep 1-19
101 limit 66 to ed=20080101-20090204
102 from 101 keep 1-28
103 limit 97 to ed=20080101-20090204
104 from 103 keep 1-32
Appendix 3. EMBASE search strategy
The following strategy was used for EMBASE:
1. (favourable or unfavourable or favorable or unfavorable).tw,kf,ot.
2. ((earl$ or low$ or limit$) adj3 (stag$ or grad$)).tw,kf,ot.
3. intermediate$.tw,kf,ot.
4. bulky.tw,kf,ot.
5. or/1-4
6. *LYMPHOMA/
7. exp HODGKIN DISEASE/
8. Germinoblastom$.tw,kf,ot.
9. Reticulolymphosarcom$.tw,kf,ot.
10. Hodgkin$.tw,kf,ot.
11. (malignan$ adj2 (lymphogranulom$ or granulom$)).tw,kf,ot.
12. or/6-11
13. exp ANTINEOPLASTIC AGENT/
14. REMISSION/
15. exp CLINICAL PROTOCOL/
16. ((consolidat$ or induct$ or maintenance or conditioning$) and (therap$ or treat$ or regimen$ or patient$)).tw,kf,ot.
17. ((therap$ or induc$) adj3 remission$).tw,kf,ot.
18. (chemotherap$ or chemo-therap$).tw,kf,ot.
19. (Antineoplast$ or anti-neoplast$).tw,kf,ot.
20. ((cytosta$ or cytotox$) adj2 (therap$ or treat$ or regimen$)).tw,kf,ot.
21. exp RADIOTHERAPY/
22. (radiotherap$ or radio-therap$).tw,kf,ot.
23. (chemoradiotherap$ or chemo-radio-therap$).tw,kf,ot.
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24. exp MULTIMODALITY CANCER THERAPY/
25. ((multimodal$ or multi-modal$) adj3 (treat$ or therap$)).tw,kf,ot.
26. exp LYMPH NODE IRRADIATION/
27. (combi$ adj3 modalit$).tw,kf,ot.
28. or/13-27
29. CLINICAL TRIAL/
30. RANDOMIZED CONTROLLED TRIALS/
31. RANDOM ALLOCATION/
32. SINGLE-BLIND METHOD/
33. DOUBLE-BLIND METHOD/
34. CROSS-OVER STUDIES/
35. PLACEBOS/
36. Randomi?ed controlled trial$.tw.
37. RCT.tw.
38. Random allocation.tw.
39. Randomly allocated.tw.
40. Allocated randomly.tw.
41. (allocated adj2 random).tw.
42. Single blind$.tw.
43. Double blind$.tw.
44. ((treble or triple) adj blind$).tw.
45. Placebo$.tw.
46. PROSPECTIVE STUDIES/
47. or/29-46
48 CASE STUDY/
49. Case report.tw.
50. ABSTRACT REPORT/ or LETTER/
51. or/48-50
52. 47 not 51
53. ANIMAL/
54. HUMAN/
55. 53 not 54
56. 52 not 55
57. 5 and 12 and 28 and 56
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Assessment of risk of bias in included studies
For quality assessment we preferred to use a “domain-based evaluation” as described in The Cochrane Collaboration’s tool for assessing
risk of bias (Higgins 2008), since it was more compatible to the risk of bias table included in the RevMan 5. We replaced the following
quality questions:
• Was treatment allocation concealed?
• Were outcome assessors blind to treatment assigned?
• Were numbers of withdraws, drop outs, lost to follow-up and protocol violations in each group stated and were less than 10% in
each arm?
• Were participants included in the analyses as part of the group to which they were allocated (intention-to-treat analyses)?
• Were the baseline characteristics similar in both groups?
Progression-free survival
Because no trials reported progression-free survival (PFS) according to our definition (time to progress or relapse or death of any cause
in all randomised patients), we accepted other progression outcomes and evaluated these as tumour control.
Adverse events
It was not planned to extract adverse events because the adverse events relevant for decision making were not expected to be reported
in the reviews. To further underline this point, all adverse events reported in the review were summarised in a table.
Summary of Findings Table
A Summary of Findings Table using the GRADE approach was included.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Combined Modality Therapy [methods]; Hodgkin Disease [∗drug therapy; pathology; ∗radiotherapy]; Randomized Controlled Trials
as Topic; Survival Analysis
MeSH check words
Humans
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